#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Family history of alcoholism and the human brain response to oral sucrose A heightened hedonic response to sweet tastes has been associated with increased alcohol preference and alcohol consumption in both humans and animals.
1-1	0-6	Family	_
1-2	7-14	history	_
1-3	15-17	of	_
1-4	18-28	alcoholism	_
1-5	29-32	and	_
1-6	33-36	the	_
1-7	37-42	human	_
1-8	43-48	brain	_
1-9	49-57	response	_
1-10	58-60	to	_
1-11	61-65	oral	_
1-12	66-73	sucrose	_
1-13	74-75	A	_
1-14	76-86	heightened	_
1-15	87-94	hedonic	_
1-16	95-103	response	_
1-17	104-106	to	_
1-18	107-112	sweet	_
1-19	113-119	tastes	_
1-20	120-123	has	_
1-21	124-128	been	_
1-22	129-139	associated	_
1-23	140-144	with	_
1-24	145-154	increased	_
1-25	155-162	alcohol	_
1-26	163-173	preference	_
1-27	174-177	and	_
1-28	178-185	alcohol	_
1-29	186-197	consumption	_
1-30	198-200	in	_
1-31	201-205	both	_
1-32	206-212	humans	_
1-33	213-216	and	_
1-34	217-224	animals	_
1-35	225-226	.	_

Text=The principal goal of this study was to examine blood oxygenation level dependent (BOLD) activation to high- and low-concentration sweet solutions in subjects who are either positive (FHP) or negative (FHN) for a family history of alcoholism.
2-1	227-230	The	_
2-2	231-240	principal	_
2-3	241-245	goal	_
2-4	246-248	of	_
2-5	249-253	this	_
2-6	254-259	study	_
2-7	260-263	was	_
2-8	264-266	to	_
2-9	267-274	examine	_
2-10	275-280	blood	_
2-11	281-292	oxygenation	_
2-12	293-298	level	_
2-13	299-308	dependent	_
2-14	309-310	(	_
2-15	311-315	BOLD	_
2-16	316-317	)	_
2-17	318-328	activation	_
2-18	329-331	to	_
2-19	332-337	high-	_
2-20	338-341	and	_
2-21	342-359	low-concentration	_
2-22	360-365	sweet	_
2-23	366-375	solutions	_
2-24	376-378	in	_
2-25	379-387	subjects	_
2-26	388-391	who	_
2-27	392-395	are	_
2-28	396-402	either	_
2-29	403-411	positive	_
2-30	412-413	(	_
2-31	414-417	FHP	_
2-32	418-419	)	_
2-33	420-422	or	_
2-34	423-431	negative	_
2-35	432-433	(	_
2-36	434-437	FHN	_
2-37	438-439	)	_
2-38	440-443	for	_
2-39	444-445	a	_
2-40	446-452	family	_
2-41	453-460	history	_
2-42	461-463	of	_
2-43	464-474	alcoholism	_
2-44	475-476	.	_

Text=Seventy-four non-treatment seeking, community-recruited, healthy volunteers (22.8 ± 1.6 SD years; 43% men) rated a range of sucrose concentrations in a taste test and underwent functional magnetic resonance imaging (fMRI) during oral delivery of water, 0.83 M, and 0.10 M sucrose.
3-1	477-489	Seventy-four	_
3-2	490-503	non-treatment	_
3-3	504-511	seeking	_
3-4	512-513	,	_
3-5	514-533	community-recruited	_
3-6	534-535	,	_
3-7	536-543	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-8	544-554	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-9	555-556	(	_
3-10	557-561	22.8	_
3-11	562-563	±	_
3-12	564-567	1.6	_
3-13	568-570	SD	_
3-14	571-576	years	_
3-15	577-578	;	_
3-16	579-581	43	_
3-17	582-583	%	_
3-18	584-587	men	_
3-19	588-589	)	_
3-20	590-595	rated	_
3-21	596-597	a	_
3-22	598-603	range	_
3-23	604-606	of	_
3-24	607-614	sucrose	_
3-25	615-629	concentrations	_
3-26	630-632	in	_
3-27	633-634	a	_
3-28	635-640	taste	_
3-29	641-645	test	_
3-30	646-649	and	_
3-31	650-659	underwent	_
3-32	660-670	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-33	671-679	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-34	680-689	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-35	690-697	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-36	698-699	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-37	700-704	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-38	705-706	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-39	707-713	during	_
3-40	714-718	oral	_
3-41	719-727	delivery	_
3-42	728-730	of	_
3-43	731-736	water	_
3-44	737-738	,	_
3-45	739-743	0.83	_
3-46	744-745	M	_
3-47	746-747	,	_
3-48	748-751	and	_
3-49	752-756	0.10	_
3-50	757-758	M	_
3-51	759-766	sucrose	_
3-52	767-768	.	_

Text=Sucrose compared to water produced robust activation in primary gustatory cortex, ventral insula, amygdala, and ventral striatum.
4-1	769-776	Sucrose	_
4-2	777-785	compared	_
4-3	786-788	to	_
4-4	789-794	water	_
4-5	795-803	produced	_
4-6	804-810	robust	_
4-7	811-821	activation	_
4-8	822-824	in	_
4-9	825-832	primary	_
4-10	833-842	gustatory	_
4-11	843-849	cortex	_
4-12	850-851	,	_
4-13	852-859	ventral	_
4-14	860-866	insula	_
4-15	867-868	,	_
4-16	869-877	amygdala	_
4-17	878-879	,	_
4-18	880-883	and	_
4-19	884-891	ventral	_
4-20	892-900	striatum	_
4-21	901-902	.	_

Text=FHP subjects displayed greater bilateral amygdala activation than FHN subjects in the low sucrose concentration (0.10 M).
5-1	903-906	FHP	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-2	907-915	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-3	916-925	displayed	_
5-4	926-933	greater	_
5-5	934-943	bilateral	_
5-6	944-952	amygdala	_
5-7	953-963	activation	_
5-8	964-968	than	_
5-9	969-972	FHN	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-10	973-981	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-11	982-984	in	_
5-12	985-988	the	_
5-13	989-992	low	_
5-14	993-1000	sucrose	_
5-15	1001-1014	concentration	_
5-16	1015-1016	(	_
5-17	1017-1021	0.10	_
5-18	1022-1023	M	_
5-19	1024-1025	)	_
5-20	1026-1027	.	_

Text=In secondary analyses, the right amygdala response to the 0.10 M sucrose was greatest in FHP women.
6-1	1028-1030	In	_
6-2	1031-1040	secondary	_
6-3	1041-1049	analyses	_
6-4	1050-1051	,	_
6-5	1052-1055	the	_
6-6	1056-1061	right	_
6-7	1062-1070	amygdala	_
6-8	1071-1079	response	_
6-9	1080-1082	to	_
6-10	1083-1086	the	_
6-11	1087-1091	0.10	_
6-12	1092-1093	M	_
6-13	1094-1101	sucrose	_
6-14	1102-1105	was	_
6-15	1106-1114	greatest	_
6-16	1115-1117	in	_
6-17	1118-1121	FHP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-18	1122-1127	women	_
6-19	1128-1129	.	_

Text=When accounting for group differences in drinks per week, the family history groups remained significantly different in their right amygdala response to 0.10 M sucrose.
7-1	1130-1134	When	_
7-2	1135-1145	accounting	_
7-3	1146-1149	for	_
7-4	1150-1155	group	_
7-5	1156-1167	differences	_
7-6	1168-1170	in	_
7-7	1171-1177	drinks	_
7-8	1178-1181	per	_
7-9	1182-1186	week	_
7-10	1187-1188	,	_
7-11	1189-1192	the	_
7-12	1193-1199	family	_
7-13	1200-1207	history	_
7-14	1208-1214	groups	_
7-15	1215-1223	remained	_
7-16	1224-1237	significantly	_
7-17	1238-1247	different	_
7-18	1248-1250	in	_
7-19	1251-1256	their	_
7-20	1257-1262	right	_
7-21	1263-1271	amygdala	_
7-22	1272-1280	response	_
7-23	1281-1283	to	_
7-24	1284-1288	0.10	_
7-25	1289-1290	M	_
7-26	1291-1298	sucrose	_
7-27	1299-1300	.	_

Text=Our findings suggest that the brain response to oral sucrose differs with a family history of alcoholism, and that this response to a mildly reinforcing primary reward might be an endophenotypic marker of alcoholism risk.
8-1	1301-1304	Our	_
8-2	1305-1313	findings	_
8-3	1314-1321	suggest	_
8-4	1322-1326	that	_
8-5	1327-1330	the	_
8-6	1331-1336	brain	_
8-7	1337-1345	response	_
8-8	1346-1348	to	_
8-9	1349-1353	oral	_
8-10	1354-1361	sucrose	_
8-11	1362-1369	differs	_
8-12	1370-1374	with	_
8-13	1375-1376	a	_
8-14	1377-1383	family	_
8-15	1384-1391	history	_
8-16	1392-1394	of	_
8-17	1395-1405	alcoholism	_
8-18	1406-1407	,	_
8-19	1408-1411	and	_
8-20	1412-1416	that	_
8-21	1417-1421	this	_
8-22	1422-1430	response	_
8-23	1431-1433	to	_
8-24	1434-1435	a	_
8-25	1436-1442	mildly	_
8-26	1443-1454	reinforcing	_
8-27	1455-1462	primary	_
8-28	1463-1469	reward	_
8-29	1470-1475	might	_
8-30	1476-1478	be	_
8-31	1479-1481	an	_
8-32	1482-1496	endophenotypic	_
8-33	1497-1503	marker	_
8-34	1504-1506	of	_
8-35	1507-1517	alcoholism	_
8-36	1518-1522	risk	_
8-37	1523-1524	.	_

Text=Highlights Studies in humans and animals have suggested sweet tastes as a trait correlate of alcohol risk.
9-1	1525-1535	Highlights	_
9-2	1536-1543	Studies	_
9-3	1544-1546	in	_
9-4	1547-1553	humans	_
9-5	1554-1557	and	_
9-6	1558-1565	animals	_
9-7	1566-1570	have	_
9-8	1571-1580	suggested	_
9-9	1581-1586	sweet	_
9-10	1587-1593	tastes	_
9-11	1594-1596	as	_
9-12	1597-1598	a	_
9-13	1599-1604	trait	_
9-14	1605-1614	correlate	_
9-15	1615-1617	of	_
9-16	1618-1625	alcohol	_
9-17	1626-1630	risk	_
9-18	1631-1632	.	_

Text=Oral sucrose resulted in robust BOLD activation of gustatory and limbic areas.
10-1	1633-1637	Oral	_
10-2	1638-1645	sucrose	_
10-3	1646-1654	resulted	_
10-4	1655-1657	in	_
10-5	1658-1664	robust	_
10-6	1665-1669	BOLD	_
10-7	1670-1680	activation	_
10-8	1681-1683	of	_
10-9	1684-1693	gustatory	_
10-10	1694-1697	and	_
10-11	1698-1704	limbic	_
10-12	1705-1710	areas	_
10-13	1711-1712	.	_

Text=Amygdala responses to 0.10 M sucrose were greatest in drinkers with family histories of alcoholism.
11-1	1713-1721	Amygdala	_
11-2	1722-1731	responses	_
11-3	1732-1734	to	_
11-4	1735-1739	0.10	_
11-5	1740-1741	M	_
11-6	1742-1749	sucrose	_
11-7	1750-1754	were	_
11-8	1755-1763	greatest	_
11-9	1764-1766	in	_
11-10	1767-1775	drinkers	_
11-11	1776-1780	with	_
11-12	1781-1787	family	_
11-13	1788-1797	histories	_
11-14	1798-1800	of	_
11-15	1801-1811	alcoholism	_
11-16	1812-1813	.	_

Text=This study is first to suggest endophenotypic brain responses to sucrose in familial alcoholism.
12-1	1814-1818	This	_
12-2	1819-1824	study	_
12-3	1825-1827	is	_
12-4	1828-1833	first	_
12-5	1834-1836	to	_
12-6	1837-1844	suggest	_
12-7	1845-1859	endophenotypic	_
12-8	1860-1865	brain	_
12-9	1866-1875	responses	_
12-10	1876-1878	to	_
12-11	1879-1886	sucrose	_
12-12	1887-1889	in	_
12-13	1890-1898	familial	_
12-14	1899-1909	alcoholism	_
12-15	1910-1911	.	_

Text=Materials and methods Subjects Seventy-four healthy, right-handed volunteers (42 women) were recruited (Table 1) and evaluated using the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA), a 35-day version of the Timeline Followback interview for habitual drinking, and the Alcohol Use Disorders Identification Test (AUDIT).
13-1	1912-1921	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	1922-1925	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	1926-1933	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	1934-1942	Subjects	_
13-5	1943-1955	Seventy-four	_
13-6	1956-1963	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-7	1964-1965	,	_
13-8	1966-1978	right-handed	_
13-9	1979-1989	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#AbnormalInvoluntaryMovementScale
13-10	1990-1991	(	_
13-11	1992-1994	42	_
13-12	1995-2000	women	_
13-13	2001-2002	)	_
13-14	2003-2007	were	_
13-15	2008-2017	recruited	_
13-16	2018-2019	(	_
13-17	2020-2025	Table	_
13-18	2026-2027	1	_
13-19	2028-2029	)	_
13-20	2030-2033	and	_
13-21	2034-2043	evaluated	_
13-22	2044-2049	using	_
13-23	2050-2053	the	_
13-24	2054-2069	Semi-Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-25	2070-2080	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-26	2081-2084	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-27	2085-2088	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-28	2089-2097	Genetics	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-29	2098-2100	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-30	2101-2111	Alcoholism	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-31	2112-2113	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-32	2114-2119	SSAGA	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-33	2120-2121	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
13-34	2122-2123	,	_
13-35	2124-2125	a	_
13-36	2126-2132	35-day	_
13-37	2133-2140	version	_
13-38	2141-2143	of	_
13-39	2144-2147	the	_
13-40	2148-2156	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
13-41	2157-2167	Followback	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
13-42	2168-2177	interview	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
13-43	2178-2181	for	_
13-44	2182-2190	habitual	_
13-45	2191-2199	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
13-46	2200-2201	,	_
13-47	2202-2205	and	_
13-48	2206-2209	the	_
13-49	2210-2217	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-50	2218-2221	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-51	2222-2231	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-52	2232-2246	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-53	2247-2251	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-54	2252-2253	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-55	2254-2259	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-56	2260-2261	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-57	2262-2263	.	_

Text=The sample consisted of 37 FHP (defined as having at least one first-degree relative using SSAGA FHA Individual Assessment Module) and 37 FHN subjects.
14-1	2264-2267	The	_
14-2	2268-2274	sample	_
14-3	2275-2284	consisted	_
14-4	2285-2287	of	_
14-5	2288-2290	37	_
14-6	2291-2294	FHP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-7	2295-2296	(	_
14-8	2297-2304	defined	_
14-9	2305-2307	as	_
14-10	2308-2314	having	_
14-11	2315-2317	at	_
14-12	2318-2323	least	_
14-13	2324-2327	one	_
14-14	2328-2340	first-degree	_
14-15	2341-2349	relative	_
14-16	2350-2355	using	_
14-17	2356-2361	SSAGA	_
14-18	2362-2365	FHA	_
14-19	2366-2376	Individual	_
14-20	2377-2387	Assessment	_
14-21	2388-2394	Module	_
14-22	2395-2396	)	_
14-23	2397-2400	and	_
14-24	2401-2403	37	_
14-25	2404-2407	FHN	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-26	2408-2416	subjects	_
14-27	2417-2418	.	_

Text=Subjects were excluded for histories of central neurological disease, head injury with loss of consciousness, and any DSM-IV Axis I diagnosis.
15-1	2419-2427	Subjects	_
15-2	2428-2432	were	_
15-3	2433-2441	excluded	_
15-4	2442-2445	for	_
15-5	2446-2455	histories	_
15-6	2456-2458	of	_
15-7	2459-2466	central	_
15-8	2467-2479	neurological	_
15-9	2480-2487	disease	_
15-10	2488-2489	,	_
15-11	2490-2494	head	_
15-12	2495-2501	injury	_
15-13	2502-2506	with	_
15-14	2507-2511	loss	_
15-15	2512-2514	of	_
15-16	2515-2528	consciousness	_
15-17	2529-2530	,	_
15-18	2531-2534	and	_
15-19	2535-2538	any	_
15-20	2539-2545	DSM-IV	_
15-21	2546-2550	Axis	_
15-22	2551-2552	I	_
15-23	2553-2562	diagnosis	_
15-24	2563-2564	.	_

Text=Subjects were not, however, excluded for prior histories of depression and/or anxiety if not currently taking medication (n = 8; 2 FHP-M, 5 FHP-F, 1 FHN-F).
16-1	2565-2573	Subjects	_
16-2	2574-2578	were	_
16-3	2579-2582	not	_
16-4	2583-2584	,	_
16-5	2585-2592	however	_
16-6	2593-2594	,	_
16-7	2595-2603	excluded	_
16-8	2604-2607	for	_
16-9	2608-2613	prior	_
16-10	2614-2623	histories	_
16-11	2624-2626	of	_
16-12	2627-2637	depression	_
16-13	2638-2644	and/or	_
16-14	2645-2652	anxiety	_
16-15	2653-2655	if	_
16-16	2656-2659	not	_
16-17	2660-2669	currently	_
16-18	2670-2676	taking	_
16-19	2677-2687	medication	_
16-20	2688-2689	(	_
16-21	2690-2691	n	_
16-22	2692-2693	=	_
16-23	2694-2695	8	_
16-24	2696-2697	;	_
16-25	2698-2699	2	_
16-26	2700-2705	FHP-M	_
16-27	2706-2707	,	_
16-28	2708-2709	5	_
16-29	2710-2715	FHP-F	_
16-30	2716-2717	,	_
16-31	2718-2719	1	_
16-32	2720-2725	FHN-F	_
16-33	2726-2727	)	_
16-34	2728-2729	.	_

Text=None of the subjects expressed interest in treatment for alcohol abuse, none reported any disorders of smell or taste, and all passed an olfactory screen (Pocket Smell Test, American Version; Sensonics, Inc.).
17-1	2730-2734	None	_
17-2	2735-2737	of	_
17-3	2738-2741	the	_
17-4	2742-2750	subjects	_
17-5	2751-2760	expressed	_
17-6	2761-2769	interest	_
17-7	2770-2772	in	_
17-8	2773-2782	treatment	_
17-9	2783-2786	for	_
17-10	2787-2794	alcohol	_
17-11	2795-2800	abuse	_
17-12	2801-2802	,	_
17-13	2803-2807	none	_
17-14	2808-2816	reported	_
17-15	2817-2820	any	_
17-16	2821-2830	disorders	_
17-17	2831-2833	of	_
17-18	2834-2839	smell	_
17-19	2840-2842	or	_
17-20	2843-2848	taste	_
17-21	2849-2850	,	_
17-22	2851-2854	and	_
17-23	2855-2858	all	_
17-24	2859-2865	passed	_
17-25	2866-2868	an	_
17-26	2869-2878	olfactory	_
17-27	2879-2885	screen	_
17-28	2886-2887	(	_
17-29	2888-2894	Pocket	_
17-30	2895-2900	Smell	_
17-31	2901-2905	Test	_
17-32	2906-2907	,	_
17-33	2908-2916	American	_
17-34	2917-2924	Version	_
17-35	2925-2926	;	_
17-36	2927-2936	Sensonics	_
17-37	2937-2938	,	_
17-38	2939-2943	Inc.	_
17-39	2944-2945	)	_
17-40	2946-2947	.	_

Text=Nineteen subjects (26%; 9 FHP-M, 4 FHP-F, 4 FHN-M, 2 FHN-F) reported nicotine use within six weeks of testing (3.74 ± 2.15 units/day), 68% (n = 13) of whom were family history positive.
18-1	2948-2956	Nineteen	_
18-2	2957-2965	subjects	_
18-3	2966-2967	(	_
18-4	2968-2970	26	_
18-5	2971-2972	%	_
18-6	2973-2974	;	_
18-7	2975-2976	9	_
18-8	2977-2982	FHP-M	http://maven.renci.org/NeuroBridge/neurobridge#Mode
18-9	2983-2984	,	_
18-10	2985-2986	4	_
18-11	2987-2992	FHP-F	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-12	2993-2994	,	_
18-13	2995-2996	4	_
18-14	2997-3002	FHN-M	http://maven.renci.org/NeuroBridge/neurobridge#Mode
18-15	3003-3004	,	_
18-16	3005-3006	2	_
18-17	3007-3012	FHN-F	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-18	3013-3014	)	_
18-19	3015-3023	reported	_
18-20	3024-3032	nicotine	_
18-21	3033-3036	use	_
18-22	3037-3043	within	_
18-23	3044-3047	six	_
18-24	3048-3053	weeks	_
18-25	3054-3056	of	_
18-26	3057-3064	testing	_
18-27	3065-3066	(	_
18-28	3067-3071	3.74	_
18-29	3072-3073	±	_
18-30	3074-3078	2.15	_
18-31	3079-3088	units/day	_
18-32	3089-3090	)	_
18-33	3091-3092	,	_
18-34	3093-3095	68	_
18-35	3096-3097	%	_
18-36	3098-3099	(	_
18-37	3100-3101	n	_
18-38	3102-3103	=	_
18-39	3104-3106	13	_
18-40	3107-3108	)	_
18-41	3109-3111	of	_
18-42	3112-3116	whom	_
18-43	3117-3121	were	_
18-44	3122-3128	family	_
18-45	3129-3136	history	_
18-46	3137-3145	positive	_
18-47	3146-3147	.	_

Text=Nicotine use was not related to drinking patterns.
19-1	3148-3156	Nicotine	_
19-2	3157-3160	use	_
19-3	3161-3164	was	_
19-4	3165-3168	not	_
19-5	3169-3176	related	_
19-6	3177-3179	to	_
19-7	3180-3188	drinking	_
19-8	3189-3197	patterns	_
19-9	3198-3199	.	_

Text=Subjects consented to a urine screen (Andwin Scientific) for commonly abused drugs [amphetamine, secobarbital, buprenorphine, oxazepam, cocaine, methylenedioxymethamphetamine, methamphetamine, morphine, methadone, opiate, oxycodone, phencyclidine, propoxyphene, and cannabinoids]; however, given its high comorbidity with alcohol, we did not exclude the one male FHN subject testing positive for marijuana use, who showed no evidence of acute intoxication, and whose last reported dose was two weeks prior to study.
20-1	3200-3208	Subjects	_
20-2	3209-3218	consented	_
20-3	3219-3221	to	_
20-4	3222-3223	a	_
20-5	3224-3229	urine	_
20-6	3230-3236	screen	_
20-7	3237-3238	(	_
20-8	3239-3245	Andwin	_
20-9	3246-3256	Scientific	_
20-10	3257-3258	)	_
20-11	3259-3262	for	_
20-12	3263-3271	commonly	_
20-13	3272-3278	abused	_
20-14	3279-3284	drugs	_
20-15	3285-3286	[	_
20-16	3287-3298	amphetamine	_
20-17	3299-3300	,	_
20-18	3301-3313	secobarbital	_
20-19	3314-3315	,	_
20-20	3316-3329	buprenorphine	_
20-21	3330-3331	,	_
20-22	3332-3340	oxazepam	_
20-23	3341-3342	,	_
20-24	3343-3350	cocaine	_
20-25	3351-3352	,	_
20-26	3353-3382	methylenedioxymethamphetamine	_
20-27	3383-3384	,	_
20-28	3385-3400	methamphetamine	_
20-29	3401-3402	,	_
20-30	3403-3411	morphine	_
20-31	3412-3413	,	_
20-32	3414-3423	methadone	_
20-33	3424-3425	,	_
20-34	3426-3432	opiate	_
20-35	3433-3434	,	_
20-36	3435-3444	oxycodone	_
20-37	3445-3446	,	_
20-38	3447-3460	phencyclidine	_
20-39	3461-3462	,	_
20-40	3463-3475	propoxyphene	_
20-41	3476-3477	,	_
20-42	3478-3481	and	_
20-43	3482-3494	cannabinoids	_
20-44	3495-3496	]	_
20-45	3497-3498	;	_
20-46	3499-3506	however	_
20-47	3507-3508	,	_
20-48	3509-3514	given	_
20-49	3515-3518	its	_
20-50	3519-3523	high	_
20-51	3524-3535	comorbidity	_
20-52	3536-3540	with	_
20-53	3541-3548	alcohol	_
20-54	3549-3550	,	_
20-55	3551-3553	we	_
20-56	3554-3557	did	_
20-57	3558-3561	not	_
20-58	3562-3569	exclude	_
20-59	3570-3573	the	_
20-60	3574-3577	one	_
20-61	3578-3582	male	_
20-62	3583-3586	FHN	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-63	3587-3594	subject	_
20-64	3595-3602	testing	_
20-65	3603-3611	positive	_
20-66	3612-3615	for	_
20-67	3616-3625	marijuana	_
20-68	3626-3629	use	_
20-69	3630-3631	,	_
20-70	3632-3635	who	_
20-71	3636-3642	showed	_
20-72	3643-3645	no	_
20-73	3646-3654	evidence	_
20-74	3655-3657	of	_
20-75	3658-3663	acute	_
20-76	3664-3676	intoxication	_
20-77	3677-3678	,	_
20-78	3679-3682	and	_
20-79	3683-3688	whose	_
20-80	3689-3693	last	_
20-81	3694-3702	reported	_
20-82	3703-3707	dose	_
20-83	3708-3711	was	_
20-84	3712-3715	two	_
20-85	3716-3721	weeks	_
20-86	3722-3727	prior	_
20-87	3728-3730	to	_
20-88	3731-3736	study	_
20-89	3737-3738	.	_

Text=There was no significant difference in the brain imaging results with this subject removed.
21-1	3739-3744	There	_
21-2	3745-3748	was	_
21-3	3749-3751	no	_
21-4	3752-3763	significant	_
21-5	3764-3774	difference	_
21-6	3775-3777	in	_
21-7	3778-3781	the	_
21-8	3782-3787	brain	_
21-9	3788-3795	imaging	_
21-10	3796-3803	results	_
21-11	3804-3808	with	_
21-12	3809-3813	this	_
21-13	3814-3821	subject	_
21-14	3822-3829	removed	_
21-15	3830-3831	.	_

Text=Experiments occurred only after each subject's written consent, as per the Indiana University Intuitional Review Board.
22-1	3832-3843	Experiments	_
22-2	3844-3852	occurred	_
22-3	3853-3857	only	_
22-4	3858-3863	after	_
22-5	3864-3868	each	_
22-6	3869-3876	subject	_
22-7	3877-3879	's	_
22-8	3880-3887	written	_
22-9	3888-3895	consent	_
22-10	3896-3897	,	_
22-11	3898-3900	as	_
22-12	3901-3904	per	_
22-13	3905-3908	the	_
22-14	3909-3916	Indiana	_
22-15	3917-3927	University	_
22-16	3928-3939	Intuitional	_
22-17	3940-3946	Review	_
22-18	3947-3952	Board	_
22-19	3953-3954	.	_

Text=Procedures Subjects arrived at ~ 7:00 am, having fasted since 11:00 pm the previous evening.
23-1	3955-3965	Procedures	_
23-2	3966-3974	Subjects	_
23-3	3975-3982	arrived	_
23-4	3983-3985	at	_
23-5	3986-3987	~	_
23-6	3988-3992	7:00	_
23-7	3993-3995	am	_
23-8	3996-3997	,	_
23-9	3998-4004	having	_
23-10	4005-4011	fasted	_
23-11	4012-4017	since	_
23-12	4018-4023	11:00	_
23-13	4024-4026	pm	_
23-14	4027-4030	the	_
23-15	4031-4039	previous	_
23-16	4040-4047	evening	_
23-17	4048-4049	.	_

Text=Height and weight were recorded, urine was collected for drug screening, and subjects were fed a standardized breakfast between 7:30–8:15 am.
24-1	4050-4056	Height	_
24-2	4057-4060	and	_
24-3	4061-4067	weight	_
24-4	4068-4072	were	_
24-5	4073-4081	recorded	_
24-6	4082-4083	,	_
24-7	4084-4089	urine	_
24-8	4090-4093	was	_
24-9	4094-4103	collected	_
24-10	4104-4107	for	_
24-11	4108-4112	drug	_
24-12	4113-4122	screening	_
24-13	4123-4124	,	_
24-14	4125-4128	and	_
24-15	4129-4137	subjects	_
24-16	4138-4142	were	_
24-17	4143-4146	fed	_
24-18	4147-4148	a	_
24-19	4149-4161	standardized	_
24-20	4162-4171	breakfast	_
24-21	4172-4179	between	_
24-22	4180-4189	7:30–8:15	_
24-23	4190-4192	am	_
24-24	4193-4194	.	_

Text=The imaging session began at approximately 11:00 am, with imaging of sucrose stimulation starting at ~ 12:00 pm (prior to which, subjects were imaged while performing one run of a monetary incentive delay task; data to be reported elsewhere).
25-1	4195-4198	The	_
25-2	4199-4206	imaging	_
25-3	4207-4214	session	_
25-4	4215-4220	began	_
25-5	4221-4223	at	_
25-6	4224-4237	approximately	_
25-7	4238-4243	11:00	_
25-8	4244-4246	am	_
25-9	4247-4248	,	_
25-10	4249-4253	with	_
25-11	4254-4261	imaging	_
25-12	4262-4264	of	_
25-13	4265-4272	sucrose	_
25-14	4273-4284	stimulation	_
25-15	4285-4293	starting	_
25-16	4294-4296	at	_
25-17	4297-4298	~	_
25-18	4299-4304	12:00	_
25-19	4305-4307	pm	_
25-20	4308-4309	(	_
25-21	4310-4315	prior	_
25-22	4316-4318	to	_
25-23	4319-4324	which	_
25-24	4325-4326	,	_
25-25	4327-4335	subjects	_
25-26	4336-4340	were	_
25-27	4341-4347	imaged	_
25-28	4348-4353	while	_
25-29	4354-4364	performing	_
25-30	4365-4368	one	_
25-31	4369-4372	run	_
25-32	4373-4375	of	_
25-33	4376-4377	a	_
25-34	4378-4386	monetary	_
25-35	4387-4396	incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
25-36	4397-4402	delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
25-37	4403-4407	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
25-38	4408-4409	;	_
25-39	4410-4414	data	_
25-40	4415-4417	to	_
25-41	4418-4420	be	_
25-42	4421-4429	reported	_
25-43	4430-4439	elsewhere	_
25-44	4440-4441	)	_
25-45	4442-4443	.	_

Text=Taste test Prior to imaging, subjects tasted and rated different molar (M) concentrations of sucrose as used in similar studies (0.05, 0.10, 0.21, 0.42, 0.83 M), prepared by dissolving table sugar in 100 ml of deionized water.
26-1	4444-4449	Taste	_
26-2	4450-4454	test	_
26-3	4455-4460	Prior	_
26-4	4461-4463	to	_
26-5	4464-4471	imaging	_
26-6	4472-4473	,	_
26-7	4474-4482	subjects	_
26-8	4483-4489	tasted	_
26-9	4490-4493	and	_
26-10	4494-4499	rated	_
26-11	4500-4509	different	_
26-12	4510-4515	molar	_
26-13	4516-4517	(	_
26-14	4518-4519	M	_
26-15	4520-4521	)	_
26-16	4522-4536	concentrations	_
26-17	4537-4539	of	_
26-18	4540-4547	sucrose	_
26-19	4548-4550	as	_
26-20	4551-4555	used	_
26-21	4556-4558	in	_
26-22	4559-4566	similar	_
26-23	4567-4574	studies	_
26-24	4575-4576	(	_
26-25	4577-4581	0.05	_
26-26	4582-4583	,	_
26-27	4584-4588	0.10	_
26-28	4589-4590	,	_
26-29	4591-4595	0.21	_
26-30	4596-4597	,	_
26-31	4598-4602	0.42	_
26-32	4603-4604	,	_
26-33	4605-4609	0.83	_
26-34	4610-4611	M	_
26-35	4612-4613	)	_
26-36	4614-4615	,	_
26-37	4616-4624	prepared	_
26-38	4625-4627	by	_
26-39	4628-4638	dissolving	_
26-40	4639-4644	table	_
26-41	4645-4650	sugar	_
26-42	4651-4653	in	_
26-43	4654-4657	100	_
26-44	4658-4660	ml	_
26-45	4661-4663	of	_
26-46	4664-4673	deionized	_
26-47	4674-4679	water	_
26-48	4680-4681	.	_

Text=Administered in three blocks, each of the five solutions was presented once per block in a randomized fashion.
27-1	4682-4694	Administered	_
27-2	4695-4697	in	_
27-3	4698-4703	three	_
27-4	4704-4710	blocks	_
27-5	4711-4712	,	_
27-6	4713-4717	each	_
27-7	4718-4720	of	_
27-8	4721-4724	the	_
27-9	4725-4729	five	_
27-10	4730-4739	solutions	_
27-11	4740-4743	was	_
27-12	4744-4753	presented	_
27-13	4754-4758	once	_
27-14	4759-4762	per	_
27-15	4763-4768	block	_
27-16	4769-4771	in	_
27-17	4772-4773	a	_
27-18	4774-4784	randomized	_
27-19	4785-4792	fashion	_
27-20	4793-4794	.	_

Text=Subjects sampled 15 ml of each solution, “ swished ” for 5 s in the mouth, and spit without swallowing.
28-1	4795-4803	Subjects	_
28-2	4804-4811	sampled	_
28-3	4812-4814	15	_
28-4	4815-4817	ml	_
28-5	4818-4820	of	_
28-6	4821-4825	each	_
28-7	4826-4834	solution	_
28-8	4835-4836	,	_
28-9	4837-4838	“	_
28-10	4839-4846	swished	_
28-11	4847-4848	”	_
28-12	4849-4852	for	_
28-13	4853-4854	5	_
28-14	4855-4856	s	_
28-15	4857-4859	in	_
28-16	4860-4863	the	_
28-17	4864-4869	mouth	_
28-18	4870-4871	,	_
28-19	4872-4875	and	_
28-20	4876-4880	spit	_
28-21	4881-4888	without	_
28-22	4889-4899	swallowing	_
28-23	4900-4901	.	_

Text=Subjects rated the intensity of sweetness and their subjective “ liking ”.
29-1	4902-4910	Subjects	_
29-2	4911-4916	rated	_
29-3	4917-4920	the	_
29-4	4921-4930	intensity	_
29-5	4931-4933	of	_
29-6	4934-4943	sweetness	_
29-7	4944-4947	and	_
29-8	4948-4953	their	_
29-9	4954-4964	subjective	_
29-10	4965-4966	“	_
29-11	4967-4973	liking	_
29-12	4974-4975	”	_
29-13	4976-4977	.	_

Text=After rating each sample, subjects cleansed their palates using ~ 10 ml of deionized water.
30-1	4978-4983	After	_
30-2	4984-4990	rating	_
30-3	4991-4995	each	_
30-4	4996-5002	sample	_
30-5	5003-5004	,	_
30-6	5005-5013	subjects	_
30-7	5014-5022	cleansed	_
30-8	5023-5028	their	_
30-9	5029-5036	palates	_
30-10	5037-5042	using	_
30-11	5043-5044	~	_
30-12	5045-5047	10	_
30-13	5048-5050	ml	_
30-14	5051-5053	of	_
30-15	5054-5063	deionized	_
30-16	5064-5069	water	_
30-17	5070-5071	.	_

Text=Gustatory stimulus paradigm Fig.
31-1	5072-5081	Gustatory	_
31-2	5082-5090	stimulus	_
31-3	5091-5099	paradigm	_
31-4	5100-5103	Fig	_
31-5	5104-5105	.	_

Text=1 visually depicts the gustatory stimulus paradigm.
32-1	5106-5107	1	_
32-2	5108-5116	visually	_
32-3	5117-5124	depicts	_
32-4	5125-5128	the	_
32-5	5129-5138	gustatory	_
32-6	5139-5147	stimulus	_
32-7	5148-5156	paradigm	_
32-8	5157-5158	.	_

Text=During imaging, gustatory stimuli were delivered using a computer controlled, five-channel gustometer in which gear pumps deliver solutions through a spray nozzle.
33-1	5159-5165	During	_
33-2	5166-5173	imaging	_
33-3	5174-5175	,	_
33-4	5176-5185	gustatory	_
33-5	5186-5193	stimuli	_
33-6	5194-5198	were	_
33-7	5199-5208	delivered	_
33-8	5209-5214	using	_
33-9	5215-5216	a	_
33-10	5217-5225	computer	_
33-11	5226-5236	controlled	_
33-12	5237-5238	,	_
33-13	5239-5251	five-channel	_
33-14	5252-5262	gustometer	_
33-15	5263-5265	in	_
33-16	5266-5271	which	_
33-17	5272-5276	gear	_
33-18	5277-5282	pumps	_
33-19	5283-5290	deliver	_
33-20	5291-5300	solutions	_
33-21	5301-5308	through	_
33-22	5309-5310	a	_
33-23	5311-5316	spray	_
33-24	5317-5323	nozzle	_
33-25	5324-5325	.	_

Text=Each delivery lightly covered the tongue with either 0.75 ml of a sucrose solution (0.83 M or 0.10 M) or a control stimulus of water with a tasteless thickening agent (ThickenUp Clear®, Nestlē Health Sciences, Vevey, Switzerland) to approximate the viscosity of the sucrose solution.
34-1	5326-5330	Each	_
34-2	5331-5339	delivery	_
34-3	5340-5347	lightly	_
34-4	5348-5355	covered	_
34-5	5356-5359	the	_
34-6	5360-5366	tongue	_
34-7	5367-5371	with	_
34-8	5372-5378	either	_
34-9	5379-5383	0.75	_
34-10	5384-5386	ml	_
34-11	5387-5389	of	_
34-12	5390-5391	a	_
34-13	5392-5399	sucrose	_
34-14	5400-5408	solution	_
34-15	5409-5410	(	_
34-16	5411-5415	0.83	_
34-17	5416-5417	M	_
34-18	5418-5420	or	_
34-19	5421-5425	0.10	_
34-20	5426-5427	M	_
34-21	5428-5429	)	_
34-22	5430-5432	or	_
34-23	5433-5434	a	_
34-24	5435-5442	control	_
34-25	5443-5451	stimulus	_
34-26	5452-5454	of	_
34-27	5455-5460	water	_
34-28	5461-5465	with	_
34-29	5466-5467	a	_
34-30	5468-5477	tasteless	_
34-31	5478-5488	thickening	_
34-32	5489-5494	agent	_
34-33	5495-5496	(	_
34-34	5497-5506	ThickenUp	_
34-35	5507-5513	Clear®	_
34-36	5514-5515	,	_
34-37	5516-5522	Nestlē	_
34-38	5523-5529	Health	_
34-39	5530-5538	Sciences	_
34-40	5539-5540	,	_
34-41	5541-5546	Vevey	_
34-42	5547-5548	,	_
34-43	5549-5560	Switzerland	_
34-44	5561-5562	)	_
34-45	5563-5565	to	_
34-46	5566-5577	approximate	_
34-47	5578-5581	the	_
34-48	5582-5591	viscosity	_
34-49	5592-5594	of	_
34-50	5595-5598	the	_
34-51	5599-5606	sucrose	_
34-52	5607-5615	solution	_
34-53	5616-5617	.	_

Text=Both sucrose and water controls were followed by 0.75 ml of thickened water (which in sucrose trials, purged the nozzle of residual sucrose).
35-1	5618-5622	Both	_
35-2	5623-5630	sucrose	_
35-3	5631-5634	and	_
35-4	5635-5640	water	_
35-5	5641-5649	controls	_
35-6	5650-5654	were	_
35-7	5655-5663	followed	_
35-8	5664-5666	by	_
35-9	5667-5671	0.75	_
35-10	5672-5674	ml	_
35-11	5675-5677	of	_
35-12	5678-5687	thickened	_
35-13	5688-5693	water	_
35-14	5694-5695	(	_
35-15	5696-5701	which	_
35-16	5702-5704	in	_
35-17	5705-5712	sucrose	_
35-18	5713-5719	trials	_
35-19	5720-5721	,	_
35-20	5722-5728	purged	_
35-21	5729-5732	the	_
35-22	5733-5739	nozzle	_
35-23	5740-5742	of	_
35-24	5743-5751	residual	_
35-25	5752-5759	sucrose	_
35-26	5760-5761	)	_
35-27	5762-5763	.	_

Text=Each subject underwent one imaging session in which each sucrose concentration was presented in three separate functional scanning runs, for a total of six functional scans per subject (three 0.83 M sucrose and three 0.10 M scans, done in an alternating order within individuals, with the starting concentration counterbalanced across individuals).
36-1	5764-5768	Each	_
36-2	5769-5776	subject	_
36-3	5777-5786	underwent	_
36-4	5787-5790	one	_
36-5	5791-5798	imaging	_
36-6	5799-5806	session	_
36-7	5807-5809	in	_
36-8	5810-5815	which	_
36-9	5816-5820	each	_
36-10	5821-5828	sucrose	_
36-11	5829-5842	concentration	_
36-12	5843-5846	was	_
36-13	5847-5856	presented	_
36-14	5857-5859	in	_
36-15	5860-5865	three	_
36-16	5866-5874	separate	_
36-17	5875-5885	functional	_
36-18	5886-5894	scanning	_
36-19	5895-5899	runs	_
36-20	5900-5901	,	_
36-21	5902-5905	for	_
36-22	5906-5907	a	_
36-23	5908-5913	total	_
36-24	5914-5916	of	_
36-25	5917-5920	six	_
36-26	5921-5931	functional	_
36-27	5932-5937	scans	_
36-28	5938-5941	per	_
36-29	5942-5949	subject	_
36-30	5950-5951	(	_
36-31	5952-5957	three	_
36-32	5958-5962	0.83	_
36-33	5963-5964	M	_
36-34	5965-5972	sucrose	_
36-35	5973-5976	and	_
36-36	5977-5982	three	_
36-37	5983-5987	0.10	_
36-38	5988-5989	M	_
36-39	5990-5995	scans	_
36-40	5996-5997	,	_
36-41	5998-6002	done	_
36-42	6003-6005	in	_
36-43	6006-6008	an	_
36-44	6009-6020	alternating	_
36-45	6021-6026	order	_
36-46	6027-6033	within	_
36-47	6034-6045	individuals	_
36-48	6046-6047	,	_
36-49	6048-6052	with	_
36-50	6053-6056	the	_
36-51	6057-6065	starting	_
36-52	6066-6079	concentration	_
36-53	6080-6095	counterbalanced	_
36-54	6096-6102	across	_
36-55	6103-6114	individuals	_
36-56	6115-6116	)	_
36-57	6117-6118	.	_

Text=Within each sucrose functional scan, there were 24 trials (7 sucrose, 17 water; pseudorandomized order for each sucrose concentration).
37-1	6119-6125	Within	_
37-2	6126-6130	each	_
37-3	6131-6138	sucrose	_
37-4	6139-6149	functional	_
37-5	6150-6154	scan	_
37-6	6155-6156	,	_
37-7	6157-6162	there	_
37-8	6163-6167	were	_
37-9	6168-6170	24	_
37-10	6171-6177	trials	_
37-11	6178-6179	(	_
37-12	6180-6181	7	_
37-13	6182-6189	sucrose	_
37-14	6190-6191	,	_
37-15	6192-6194	17	_
37-16	6195-6200	water	_
37-17	6201-6202	;	_
37-18	6203-6219	pseudorandomized	_
37-19	6220-6225	order	_
37-20	6226-6229	for	_
37-21	6230-6234	each	_
37-22	6235-6242	sucrose	_
37-23	6243-6256	concentration	_
37-24	6257-6258	)	_
37-25	6259-6260	.	_

Text=This resulted in 21 sucrose and 51 water trials for each concentration.
38-1	6261-6265	This	_
38-2	6266-6274	resulted	_
38-3	6275-6277	in	_
38-4	6278-6280	21	_
38-5	6281-6288	sucrose	_
38-6	6289-6292	and	_
38-7	6293-6295	51	_
38-8	6296-6301	water	_
38-9	6302-6308	trials	_
38-10	6309-6312	for	_
38-11	6313-6317	each	_
38-12	6318-6331	concentration	_
38-13	6332-6333	.	_

Text=Subjects were alerted to impending spray delivery by the text “ READY ” as projected onto a screen at the rear of the scanner, with “ SPRAY ” being displayed while the solution was presented.
39-1	6334-6342	Subjects	_
39-2	6343-6347	were	_
39-3	6348-6355	alerted	_
39-4	6356-6358	to	_
39-5	6359-6368	impending	_
39-6	6369-6374	spray	_
39-7	6375-6383	delivery	_
39-8	6384-6386	by	_
39-9	6387-6390	the	_
39-10	6391-6395	text	_
39-11	6396-6397	“	_
39-12	6398-6403	READY	_
39-13	6404-6405	”	_
39-14	6406-6408	as	_
39-15	6409-6418	projected	_
39-16	6419-6423	onto	_
39-17	6424-6425	a	_
39-18	6426-6432	screen	_
39-19	6433-6435	at	_
39-20	6436-6439	the	_
39-21	6440-6444	rear	_
39-22	6445-6447	of	_
39-23	6448-6451	the	_
39-24	6452-6459	scanner	_
39-25	6460-6461	,	_
39-26	6462-6466	with	_
39-27	6467-6468	“	_
39-28	6469-6474	SPRAY	_
39-29	6475-6476	”	_
39-30	6477-6482	being	_
39-31	6483-6492	displayed	_
39-32	6493-6498	while	_
39-33	6499-6502	the	_
39-34	6503-6511	solution	_
39-35	6512-6515	was	_
39-36	6516-6525	presented	_
39-37	6526-6527	.	_

Text=Subjects were asked to hold the solution in their mouth until prompted to swallow by the visual command “ SWALLOW ” (jittered 1–3 s after sprays).
40-1	6528-6536	Subjects	_
40-2	6537-6541	were	_
40-3	6542-6547	asked	_
40-4	6548-6550	to	_
40-5	6551-6555	hold	_
40-6	6556-6559	the	_
40-7	6560-6568	solution	_
40-8	6569-6571	in	_
40-9	6572-6577	their	_
40-10	6578-6583	mouth	_
40-11	6584-6589	until	_
40-12	6590-6598	prompted	_
40-13	6599-6601	to	_
40-14	6602-6609	swallow	_
40-15	6610-6612	by	_
40-16	6613-6616	the	_
40-17	6617-6623	visual	_
40-18	6624-6631	command	_
40-19	6632-6633	“	_
40-20	6634-6641	SWALLOW	_
40-21	6642-6643	”	_
40-22	6644-6645	(	_
40-23	6646-6654	jittered	_
40-24	6655-6658	1–3	_
40-25	6659-6660	s	_
40-26	6661-6666	after	_
40-27	6667-6673	sprays	_
40-28	6674-6675	)	_
40-29	6676-6677	.	_

Text=To maximize taste contrast, only water controls that immediately followed a preceding water trial were used for the [Sucrose> Water] contrast, resulting in comparisons of 21 trials of each sucrose concentration and 33 water trials for each subject.
41-1	6678-6680	To	_
41-2	6681-6689	maximize	_
41-3	6690-6695	taste	_
41-4	6696-6704	contrast	_
41-5	6705-6706	,	_
41-6	6707-6711	only	_
41-7	6712-6717	water	_
41-8	6718-6726	controls	_
41-9	6727-6731	that	_
41-10	6732-6743	immediately	_
41-11	6744-6752	followed	_
41-12	6753-6754	a	_
41-13	6755-6764	preceding	_
41-14	6765-6770	water	_
41-15	6771-6776	trial	_
41-16	6777-6781	were	_
41-17	6782-6786	used	_
41-18	6787-6790	for	_
41-19	6791-6794	the	_
41-20	6795-6796	[	_
41-21	6797-6804	Sucrose	_
41-22	6805-6806	>	_
41-23	6807-6812	Water	_
41-24	6813-6814	]	_
41-25	6815-6823	contrast	_
41-26	6824-6825	,	_
41-27	6826-6835	resulting	_
41-28	6836-6838	in	_
41-29	6839-6850	comparisons	_
41-30	6851-6853	of	_
41-31	6854-6856	21	_
41-32	6857-6863	trials	_
41-33	6864-6866	of	_
41-34	6867-6871	each	_
41-35	6872-6879	sucrose	_
41-36	6880-6893	concentration	_
41-37	6894-6897	and	_
41-38	6898-6900	33	_
41-39	6901-6906	water	_
41-40	6907-6913	trials	_
41-41	6914-6917	for	_
41-42	6918-6922	each	_
41-43	6923-6930	subject	_
41-44	6931-6932	.	_

Text=Following each scan, 1.5 ml (or more as chosen by the subject) of thickened water was delivered to the subject to rinse the mouth, with the opportunity to administer further rinses as needed by subjects individually.
42-1	6933-6942	Following	_
42-2	6943-6947	each	_
42-3	6948-6952	scan	_
42-4	6953-6954	,	_
42-5	6955-6958	1.5	_
42-6	6959-6961	ml	_
42-7	6962-6963	(	_
42-8	6964-6966	or	_
42-9	6967-6971	more	_
42-10	6972-6974	as	_
42-11	6975-6981	chosen	_
42-12	6982-6984	by	_
42-13	6985-6988	the	_
42-14	6989-6996	subject	_
42-15	6997-6998	)	_
42-16	6999-7001	of	_
42-17	7002-7011	thickened	_
42-18	7012-7017	water	_
42-19	7018-7021	was	_
42-20	7022-7031	delivered	_
42-21	7032-7034	to	_
42-22	7035-7038	the	_
42-23	7039-7046	subject	_
42-24	7047-7049	to	_
42-25	7050-7055	rinse	_
42-26	7056-7059	the	_
42-27	7060-7065	mouth	_
42-28	7066-7067	,	_
42-29	7068-7072	with	_
42-30	7073-7076	the	_
42-31	7077-7088	opportunity	_
42-32	7089-7091	to	_
42-33	7092-7102	administer	_
42-34	7103-7110	further	_
42-35	7111-7117	rinses	_
42-36	7118-7120	as	_
42-37	7121-7127	needed	_
42-38	7128-7130	by	_
42-39	7131-7139	subjects	_
42-40	7140-7152	individually	_
42-41	7153-7154	.	_

Text=Intra-MRI assessment Prior to the first sucrose scan, subjects rated baseline hunger, thirst, and sweet and salt craving.
43-1	7155-7164	Intra-MRI	_
43-2	7165-7175	assessment	_
43-3	7176-7181	Prior	_
43-4	7182-7184	to	_
43-5	7185-7188	the	_
43-6	7189-7194	first	_
43-7	7195-7202	sucrose	_
43-8	7203-7207	scan	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
43-9	7208-7209	,	_
43-10	7210-7218	subjects	_
43-11	7219-7224	rated	_
43-12	7225-7233	baseline	_
43-13	7234-7240	hunger	_
43-14	7241-7242	,	_
43-15	7243-7249	thirst	_
43-16	7250-7251	,	_
43-17	7252-7255	and	_
43-18	7256-7261	sweet	_
43-19	7262-7265	and	_
43-20	7266-7270	salt	_
43-21	7271-7278	craving	_
43-22	7279-7280	.	_

Text=Following the first two and final two functional scans, subjects rated hunger, thirst, sweet and salt cravings, perceived sweetness, liking of the sucrose solution in the prior scan, and desire to increase or decrease solution sweetness.
44-1	7281-7290	Following	_
44-2	7291-7294	the	_
44-3	7295-7300	first	_
44-4	7301-7304	two	_
44-5	7305-7308	and	_
44-6	7309-7314	final	_
44-7	7315-7318	two	_
44-8	7319-7329	functional	_
44-9	7330-7335	scans	_
44-10	7336-7337	,	_
44-11	7338-7346	subjects	_
44-12	7347-7352	rated	_
44-13	7353-7359	hunger	_
44-14	7360-7361	,	_
44-15	7362-7368	thirst	_
44-16	7369-7370	,	_
44-17	7371-7376	sweet	_
44-18	7377-7380	and	_
44-19	7381-7385	salt	_
44-20	7386-7394	cravings	_
44-21	7395-7396	,	_
44-22	7397-7406	perceived	_
44-23	7407-7416	sweetness	_
44-24	7417-7418	,	_
44-25	7419-7425	liking	_
44-26	7426-7428	of	_
44-27	7429-7432	the	_
44-28	7433-7440	sucrose	_
44-29	7441-7449	solution	_
44-30	7450-7452	in	_
44-31	7453-7456	the	_
44-32	7457-7462	prior	_
44-33	7463-7467	scan	_
44-34	7468-7469	,	_
44-35	7470-7473	and	_
44-36	7474-7480	desire	_
44-37	7481-7483	to	_
44-38	7484-7492	increase	_
44-39	7493-7495	or	_
44-40	7496-7504	decrease	_
44-41	7505-7513	solution	_
44-42	7514-7523	sweetness	_
44-43	7524-7525	.	_

Text=Subjects made rated the sucrose solutions following the first and last pair of high/low concentration scans so as to bracket all sucrose functional scans, and to avoid “ rating fatigue ” from repeated questioning.
45-1	7526-7534	Subjects	_
45-2	7535-7539	made	_
45-3	7540-7545	rated	_
45-4	7546-7549	the	_
45-5	7550-7557	sucrose	_
45-6	7558-7567	solutions	_
45-7	7568-7577	following	_
45-8	7578-7581	the	_
45-9	7582-7587	first	_
45-10	7588-7591	and	_
45-11	7592-7596	last	_
45-12	7597-7601	pair	_
45-13	7602-7604	of	_
45-14	7605-7613	high/low	_
45-15	7614-7627	concentration	_
45-16	7628-7633	scans	_
45-17	7634-7636	so	_
45-18	7637-7639	as	_
45-19	7640-7642	to	_
45-20	7643-7650	bracket	_
45-21	7651-7654	all	_
45-22	7655-7662	sucrose	_
45-23	7663-7673	functional	_
45-24	7674-7679	scans	_
45-25	7680-7681	,	_
45-26	7682-7685	and	_
45-27	7686-7688	to	_
45-28	7689-7694	avoid	_
45-29	7695-7696	“	_
45-30	7697-7703	rating	_
45-31	7704-7711	fatigue	_
45-32	7712-7713	”	_
45-33	7714-7718	from	_
45-34	7719-7727	repeated	_
45-35	7728-7739	questioning	_
45-36	7740-7741	.	_

Text=Image acquisition Subjects were imaged on a Siemens 3 T Magnetom Prisma (Erlangen, Germany) scanner using a 64-channel head coil array.
46-1	7742-7747	Image	_
46-2	7748-7759	acquisition	_
46-3	7760-7768	Subjects	_
46-4	7769-7773	were	_
46-5	7774-7780	imaged	_
46-6	7781-7783	on	_
46-7	7784-7785	a	_
46-8	7786-7793	Siemens	_
46-9	7794-7795	3	http://maven.renci.org/NeuroBridge/neurobridge#2Level
46-10	7796-7797	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
46-11	7798-7806	Magnetom	http://maven.renci.org/NeuroBridge/neurobridge#2Level
46-12	7807-7813	Prisma	http://maven.renci.org/NeuroBridge/neurobridge#2Level
46-13	7814-7815	(	_
46-14	7816-7824	Erlangen	_
46-15	7825-7826	,	_
46-16	7827-7834	Germany	_
46-17	7835-7836	)	_
46-18	7837-7844	scanner	_
46-19	7845-7850	using	_
46-20	7851-7852	a	_
46-21	7853-7863	64-channel	_
46-22	7864-7868	head	_
46-23	7869-7873	coil	_
46-24	7874-7879	array	_
46-25	7880-7881	.	_

Text=A high-resolution anatomic volume (1.05 × 1.05 × 1.2 mm3 voxels, 3D magnetization prepared rapid gradient echo; MPRAGE) was used to position functional, blood oxygenation level dependent (BOLD) contrast sensitive data acquisition (gradient echo, echo-planar imaging [EPI], 164 measurements, repetition/echo time TR/TE = 2110/29 ms, flip angle 78°, field-of-view 220 × 220 mm, matrix 80 × 80, 39 interleaved 3 mm thick slices, 2.75 × 2.75 × 3.0 mm3 voxels, GRAPPA acceleration factor 2).
47-1	7882-7883	A	_
47-2	7884-7899	high-resolution	_
47-3	7900-7908	anatomic	_
47-4	7909-7915	volume	_
47-5	7916-7917	(	_
47-6	7918-7922	1.05	_
47-7	7923-7924	×	_
47-8	7925-7929	1.05	_
47-9	7930-7931	×	_
47-10	7932-7935	1.2	_
47-11	7936-7939	mm3	_
47-12	7940-7946	voxels	_
47-13	7947-7948	,	_
47-14	7949-7951	3D	_
47-15	7952-7965	magnetization	_
47-16	7966-7974	prepared	_
47-17	7975-7980	rapid	_
47-18	7981-7989	gradient	_
47-19	7990-7994	echo	_
47-20	7995-7996	;	_
47-21	7997-8003	MPRAGE	_
47-22	8004-8005	)	_
47-23	8006-8009	was	_
47-24	8010-8014	used	_
47-25	8015-8017	to	_
47-26	8018-8026	position	_
47-27	8027-8037	functional	_
47-28	8038-8039	,	_
47-29	8040-8045	blood	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
47-30	8046-8057	oxygenation	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
47-31	8058-8063	level	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
47-32	8064-8073	dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
47-33	8074-8075	(	_
47-34	8076-8080	BOLD	_
47-35	8081-8082	)	_
47-36	8083-8091	contrast	_
47-37	8092-8101	sensitive	_
47-38	8102-8106	data	_
47-39	8107-8118	acquisition	_
47-40	8119-8120	(	_
47-41	8121-8129	gradient	_
47-42	8130-8134	echo	_
47-43	8135-8136	,	_
47-44	8137-8148	echo-planar	_
47-45	8149-8156	imaging	_
47-46	8157-8158	[	_
47-47	8159-8162	EPI	_
47-48	8163-8164	]	_
47-49	8165-8166	,	_
47-50	8167-8170	164	_
47-51	8171-8183	measurements	_
47-52	8184-8185	,	_
47-53	8186-8201	repetition/echo	_
47-54	8202-8206	time	_
47-55	8207-8212	TR/TE	_
47-56	8213-8214	=	_
47-57	8215-8222	2110/29	_
47-58	8223-8225	ms	_
47-59	8226-8227	,	_
47-60	8228-8232	flip	_
47-61	8233-8238	angle	_
47-62	8239-8242	78°	_
47-63	8243-8244	,	_
47-64	8245-8258	field-of-view	_
47-65	8259-8262	220	_
47-66	8263-8264	×	_
47-67	8265-8268	220	_
47-68	8269-8271	mm	_
47-69	8272-8273	,	_
47-70	8274-8280	matrix	_
47-71	8281-8283	80	_
47-72	8284-8285	×	_
47-73	8286-8288	80	_
47-74	8289-8290	,	_
47-75	8291-8293	39	_
47-76	8294-8305	interleaved	_
47-77	8306-8307	3	_
47-78	8308-8310	mm	_
47-79	8311-8316	thick	_
47-80	8317-8323	slices	_
47-81	8324-8325	,	_
47-82	8326-8330	2.75	_
47-83	8331-8332	×	_
47-84	8333-8337	2.75	_
47-85	8338-8339	×	_
47-86	8340-8343	3.0	_
47-87	8344-8347	mm3	_
47-88	8348-8354	voxels	_
47-89	8355-8356	,	_
47-90	8357-8363	GRAPPA	_
47-91	8364-8376	acceleration	_
47-92	8377-8383	factor	_
47-93	8384-8385	2	_
47-94	8386-8387	)	_
47-95	8388-8389	.	_

Text=The total duration of functional imaging was 50–55 min, which included brief instructions, six BOLD scans, intra-MRI assessment questions, and time for post-scan water spray delivery and subjective ratings after BOLD scans.
48-1	8390-8393	The	_
48-2	8394-8399	total	_
48-3	8400-8408	duration	_
48-4	8409-8411	of	_
48-5	8412-8422	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
48-6	8423-8430	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
48-7	8431-8434	was	_
48-8	8435-8440	50–55	_
48-9	8441-8444	min	_
48-10	8445-8446	,	_
48-11	8447-8452	which	_
48-12	8453-8461	included	_
48-13	8462-8467	brief	_
48-14	8468-8480	instructions	_
48-15	8481-8482	,	_
48-16	8483-8486	six	_
48-17	8487-8491	BOLD	_
48-18	8492-8497	scans	_
48-19	8498-8499	,	_
48-20	8500-8509	intra-MRI	_
48-21	8510-8520	assessment	_
48-22	8521-8530	questions	_
48-23	8531-8532	,	_
48-24	8533-8536	and	_
48-25	8537-8541	time	_
48-26	8542-8545	for	_
48-27	8546-8555	post-scan	_
48-28	8556-8561	water	_
48-29	8562-8567	spray	_
48-30	8568-8576	delivery	_
48-31	8577-8580	and	_
48-32	8581-8591	subjective	_
48-33	8592-8599	ratings	_
48-34	8600-8605	after	_
48-35	8606-8610	BOLD	_
48-36	8611-8616	scans	_
48-37	8617-8618	.	_

Text=A gradient echo field mapping scan (TR = 355 ms, TE1/TE2 = 3.86/6.32 ms) with an imaging volume and voxel size identical to BOLD EPI was acquired prior to the first BOLD scan.
49-1	8619-8620	A	_
49-2	8621-8629	gradient	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
49-3	8630-8634	echo	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
49-4	8635-8640	field	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
49-5	8641-8648	mapping	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
49-6	8649-8653	scan	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
49-7	8654-8655	(	_
49-8	8656-8658	TR	_
49-9	8659-8660	=	_
49-10	8661-8664	355	_
49-11	8665-8667	ms	_
49-12	8668-8669	,	_
49-13	8670-8677	TE1/TE2	_
49-14	8678-8679	=	_
49-15	8680-8689	3.86/6.32	_
49-16	8690-8692	ms	_
49-17	8693-8694	)	_
49-18	8695-8699	with	_
49-19	8700-8702	an	_
49-20	8703-8710	imaging	_
49-21	8711-8717	volume	_
49-22	8718-8721	and	_
49-23	8722-8727	voxel	_
49-24	8728-8732	size	_
49-25	8733-8742	identical	_
49-26	8743-8745	to	_
49-27	8746-8750	BOLD	_
49-28	8751-8754	EPI	_
49-29	8755-8758	was	_
49-30	8759-8767	acquired	_
49-31	8768-8773	prior	_
49-32	8774-8776	to	_
49-33	8777-8780	the	_
49-34	8781-8786	first	_
49-35	8787-8791	BOLD	_
49-36	8792-8796	scan	_
49-37	8797-8798	.	_

Text=This 59 s scan with an advanced B0 shim mode adjustment optimized the field homogeneity and facilitated the BOLD EPI volume distortion evaluation and unwarping.
50-1	8799-8803	This	_
50-2	8804-8806	59	_
50-3	8807-8808	s	_
50-4	8809-8813	scan	_
50-5	8814-8818	with	_
50-6	8819-8821	an	_
50-7	8822-8830	advanced	_
50-8	8831-8833	B0	_
50-9	8834-8838	shim	_
50-10	8839-8843	mode	_
50-11	8844-8854	adjustment	_
50-12	8855-8864	optimized	_
50-13	8865-8868	the	_
50-14	8869-8874	field	_
50-15	8875-8886	homogeneity	_
50-16	8887-8890	and	_
50-17	8891-8902	facilitated	_
50-18	8903-8906	the	_
50-19	8907-8911	BOLD	_
50-20	8912-8915	EPI	_
50-21	8916-8922	volume	_
50-22	8923-8933	distortion	_
50-23	8934-8944	evaluation	_
50-24	8945-8948	and	_
50-25	8949-8958	unwarping	_
50-26	8959-8960	.	_

Text=This procedure yielded improved localization across the brain, most notably in the ventral striatal and frontal areas.
51-1	8961-8965	This	_
51-2	8966-8975	procedure	_
51-3	8976-8983	yielded	_
51-4	8984-8992	improved	_
51-5	8993-9005	localization	_
51-6	9006-9012	across	_
51-7	9013-9016	the	_
51-8	9017-9022	brain	_
51-9	9023-9024	,	_
51-10	9025-9029	most	_
51-11	9030-9037	notably	_
51-12	9038-9040	in	_
51-13	9041-9044	the	_
51-14	9045-9052	ventral	_
51-15	9053-9061	striatal	_
51-16	9062-9065	and	_
51-17	9066-9073	frontal	_
51-18	9074-9079	areas	_
51-19	9080-9081	.	_

Text=Subjects' head movement and motion-related artifacts were minimized using foam pads and real time prospective acquisition motion correction, with additional steps accounting for head motion detailed in the image analysis below.
52-1	9082-9090	Subjects	_
52-2	9091-9092	'	_
52-3	9093-9097	head	_
52-4	9098-9106	movement	_
52-5	9107-9110	and	_
52-6	9111-9125	motion-related	_
52-7	9126-9135	artifacts	_
52-8	9136-9140	were	_
52-9	9141-9150	minimized	_
52-10	9151-9156	using	_
52-11	9157-9161	foam	_
52-12	9162-9166	pads	_
52-13	9167-9170	and	_
52-14	9171-9175	real	_
52-15	9176-9180	time	_
52-16	9181-9192	prospective	_
52-17	9193-9204	acquisition	_
52-18	9205-9211	motion	_
52-19	9212-9222	correction	_
52-20	9223-9224	,	_
52-21	9225-9229	with	_
52-22	9230-9240	additional	_
52-23	9241-9246	steps	_
52-24	9247-9257	accounting	_
52-25	9258-9261	for	_
52-26	9262-9266	head	_
52-27	9267-9273	motion	_
52-28	9274-9282	detailed	_
52-29	9283-9285	in	_
52-30	9286-9289	the	_
52-31	9290-9295	image	_
52-32	9296-9304	analysis	_
52-33	9305-9310	below	_
52-34	9311-9312	.	_

Text=Image analysis Image preprocessing included BOLD volume unwarping using topup/applytopup (Oxford Center for Functional MRI of the Brain Software Library; FSL,), with slice-time acquisition correction, rigid-body realignment, and co-registration implemented in SPM8 (Wellcome Department of Imaging Neuroscience, University College, London, UK).
53-1	9313-9318	Image	_
53-2	9319-9327	analysis	_
53-3	9328-9333	Image	_
53-4	9334-9347	preprocessing	_
53-5	9348-9356	included	_
53-6	9357-9361	BOLD	_
53-7	9362-9368	volume	_
53-8	9369-9378	unwarping	_
53-9	9379-9384	using	_
53-10	9385-9401	topup/applytopup	_
53-11	9402-9403	(	_
53-12	9404-9410	Oxford	_
53-13	9411-9417	Center	_
53-14	9418-9421	for	_
53-15	9422-9432	Functional	_
53-16	9433-9436	MRI	_
53-17	9437-9439	of	_
53-18	9440-9443	the	_
53-19	9444-9449	Brain	_
53-20	9450-9458	Software	_
53-21	9459-9466	Library	_
53-22	9467-9468	;	_
53-23	9469-9472	FSL	_
53-24	9473-9474	,	_
53-25	9475-9476	)	_
53-26	9477-9478	,	_
53-27	9479-9483	with	_
53-28	9484-9494	slice-time	_
53-29	9495-9506	acquisition	_
53-30	9507-9517	correction	_
53-31	9518-9519	,	_
53-32	9520-9530	rigid-body	_
53-33	9531-9542	realignment	_
53-34	9543-9544	,	_
53-35	9545-9548	and	_
53-36	9549-9564	co-registration	_
53-37	9565-9576	implemented	_
53-38	9577-9579	in	_
53-39	9580-9584	SPM8	_
53-40	9585-9586	(	_
53-41	9587-9595	Wellcome	_
53-42	9596-9606	Department	_
53-43	9607-9609	of	_
53-44	9610-9617	Imaging	_
53-45	9618-9630	Neuroscience	_
53-46	9631-9632	,	_
53-47	9633-9643	University	_
53-48	9644-9651	College	_
53-49	9652-9653	,	_
53-50	9654-9660	London	_
53-51	9661-9662	,	_
53-52	9663-9665	UK	_
53-53	9666-9667	)	_
53-54	9668-9669	.	_

Text=Each subject's MPRAGE image was segmented with SPM8 and parameters from this nonlinear transformation were used to convert the subject's structural MRI and realigned, co-registered BOLD volumes into Montreal Neurological Institute (MNI) stereotactic space.
54-1	9670-9674	Each	_
54-2	9675-9682	subject	_
54-3	9683-9685	's	_
54-4	9686-9692	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
54-5	9693-9698	image	_
54-6	9699-9702	was	_
54-7	9703-9712	segmented	_
54-8	9713-9717	with	_
54-9	9718-9722	SPM8	_
54-10	9723-9726	and	_
54-11	9727-9737	parameters	_
54-12	9738-9742	from	_
54-13	9743-9747	this	_
54-14	9748-9757	nonlinear	_
54-15	9758-9772	transformation	_
54-16	9773-9777	were	_
54-17	9778-9782	used	_
54-18	9783-9785	to	_
54-19	9786-9793	convert	_
54-20	9794-9797	the	_
54-21	9798-9805	subject	_
54-22	9806-9808	's	_
54-23	9809-9819	structural	_
54-24	9820-9823	MRI	_
54-25	9824-9827	and	_
54-26	9828-9837	realigned	_
54-27	9838-9839	,	_
54-28	9840-9853	co-registered	_
54-29	9854-9858	BOLD	_
54-30	9859-9866	volumes	_
54-31	9867-9871	into	_
54-32	9872-9880	Montreal	_
54-33	9881-9893	Neurological	_
54-34	9894-9903	Institute	_
54-35	9904-9905	(	_
54-36	9906-9909	MNI	_
54-37	9910-9911	)	_
54-38	9912-9924	stereotactic	_
54-39	9925-9930	space	_
54-40	9931-9932	.	_

Text=The resulting volumes were interpolated to 2 mm/side isotropic voxels and smoothed by a 6 mm full-width at half-maximum isotropic Gaussian kernel.
55-1	9933-9936	The	_
55-2	9937-9946	resulting	_
55-3	9947-9954	volumes	_
55-4	9955-9959	were	_
55-5	9960-9972	interpolated	_
55-6	9973-9975	to	_
55-7	9976-9977	2	_
55-8	9978-9985	mm/side	_
55-9	9986-9995	isotropic	_
55-10	9996-10002	voxels	_
55-11	10003-10006	and	_
55-12	10007-10015	smoothed	_
55-13	10016-10018	by	_
55-14	10019-10020	a	_
55-15	10021-10022	6	_
55-16	10023-10025	mm	_
55-17	10026-10036	full-width	_
55-18	10037-10039	at	_
55-19	10040-10052	half-maximum	_
55-20	10053-10062	isotropic	_
55-21	10063-10071	Gaussian	_
55-22	10072-10078	kernel	_
55-23	10079-10080	.	_

Text=Within-subject fixed effects of the BOLD response to stimulus trials were estimated using SPM's canonical hemodynamic response function with time and dispersion derivatives.
56-1	10081-10095	Within-subject	_
56-2	10096-10101	fixed	_
56-3	10102-10109	effects	_
56-4	10110-10112	of	_
56-5	10113-10116	the	_
56-6	10117-10121	BOLD	_
56-7	10122-10130	response	_
56-8	10131-10133	to	_
56-9	10134-10142	stimulus	_
56-10	10143-10149	trials	_
56-11	10150-10154	were	_
56-12	10155-10164	estimated	_
56-13	10165-10170	using	_
56-14	10171-10174	SPM	_
56-15	10175-10177	's	_
56-16	10178-10187	canonical	_
56-17	10188-10199	hemodynamic	_
56-18	10200-10208	response	_
56-19	10209-10217	function	_
56-20	10218-10222	with	_
56-21	10223-10227	time	_
56-22	10228-10231	and	_
56-23	10232-10242	dispersion	_
56-24	10243-10254	derivatives	_
56-25	10255-10256	.	_

Text=Sucrose and water trial conditions were modeled to an onset coinciding with gustometer pump activation and durations of 3 s. Swallowing was a condition of no interest, with onsets given by the visual cue appearance.
57-1	10257-10264	Sucrose	_
57-2	10265-10268	and	_
57-3	10269-10274	water	_
57-4	10275-10280	trial	_
57-5	10281-10291	conditions	_
57-6	10292-10296	were	_
57-7	10297-10304	modeled	_
57-8	10305-10307	to	_
57-9	10308-10310	an	_
57-10	10311-10316	onset	_
57-11	10317-10327	coinciding	_
57-12	10328-10332	with	_
57-13	10333-10343	gustometer	_
57-14	10344-10348	pump	_
57-15	10349-10359	activation	_
57-16	10360-10363	and	_
57-17	10364-10373	durations	_
57-18	10374-10376	of	_
57-19	10377-10378	3	_
57-20	10379-10381	s.	_
57-21	10382-10392	Swallowing	_
57-22	10393-10396	was	_
57-23	10397-10398	a	_
57-24	10399-10408	condition	_
57-25	10409-10411	of	_
57-26	10412-10414	no	_
57-27	10415-10423	interest	_
57-28	10424-10425	,	_
57-29	10426-10430	with	_
57-30	10431-10437	onsets	_
57-31	10438-10443	given	_
57-32	10444-10446	by	_
57-33	10447-10450	the	_
57-34	10451-10457	visual	_
57-35	10458-10461	cue	_
57-36	10462-10472	appearance	_
57-37	10473-10474	.	_

Text=We included, as multiple regressors, six head motion parameters from the SPM8 realignment and two FSL-derived metrics (frame displacement and DVARS from fsl_motion_outliers) recommended for tagging outlier BOLD volumes corrupted by large motion.
58-1	10475-10477	We	_
58-2	10478-10486	included	_
58-3	10487-10488	,	_
58-4	10489-10491	as	_
58-5	10492-10500	multiple	_
58-6	10501-10511	regressors	_
58-7	10512-10513	,	_
58-8	10514-10517	six	_
58-9	10518-10522	head	_
58-10	10523-10529	motion	_
58-11	10530-10540	parameters	_
58-12	10541-10545	from	_
58-13	10546-10549	the	_
58-14	10550-10554	SPM8	_
58-15	10555-10566	realignment	_
58-16	10567-10570	and	_
58-17	10571-10574	two	_
58-18	10575-10586	FSL-derived	_
58-19	10587-10594	metrics	_
58-20	10595-10596	(	_
58-21	10597-10602	frame	_
58-22	10603-10615	displacement	_
58-23	10616-10619	and	_
58-24	10620-10625	DVARS	_
58-25	10626-10630	from	_
58-26	10631-10650	fsl_motion_outliers	_
58-27	10651-10652	)	_
58-28	10653-10664	recommended	_
58-29	10665-10668	for	_
58-30	10669-10676	tagging	_
58-31	10677-10684	outlier	_
58-32	10685-10689	BOLD	_
58-33	10690-10697	volumes	_
58-34	10698-10707	corrupted	_
58-35	10708-10710	by	_
58-36	10711-10716	large	_
58-37	10717-10723	motion	_
58-38	10724-10725	.	_

Text=A mixed linear model found no difference in outliers within any factor.
59-1	10726-10727	A	_
59-2	10728-10733	mixed	_
59-3	10734-10740	linear	_
59-4	10741-10746	model	_
59-5	10747-10752	found	_
59-6	10753-10755	no	_
59-7	10756-10766	difference	_
59-8	10767-10769	in	_
59-9	10770-10778	outliers	_
59-10	10779-10785	within	_
59-11	10786-10789	any	_
59-12	10790-10796	factor	_
59-13	10797-10798	.	_

Text=An autoregressive AR (1) model accounted for serial correlations, while a high-pass filter was set (1/128 Hz) to remove low-frequency noise.
60-1	10799-10801	An	_
60-2	10802-10816	autoregressive	_
60-3	10817-10819	AR	_
60-4	10820-10821	(	_
60-5	10822-10823	1	_
60-6	10824-10825	)	_
60-7	10826-10831	model	_
60-8	10832-10841	accounted	_
60-9	10842-10845	for	_
60-10	10846-10852	serial	_
60-11	10853-10865	correlations	_
60-12	10866-10867	,	_
60-13	10868-10873	while	_
60-14	10874-10875	a	_
60-15	10876-10885	high-pass	_
60-16	10886-10892	filter	_
60-17	10893-10896	was	_
60-18	10897-10900	set	_
60-19	10901-10902	(	_
60-20	10903-10908	1/128	_
60-21	10909-10911	Hz	_
60-22	10912-10913	)	_
60-23	10914-10916	to	_
60-24	10917-10923	remove	_
60-25	10924-10937	low-frequency	_
60-26	10938-10943	noise	_
60-27	10944-10945	.	_

Text=Statistical analysis The contrasts of [0.83 M Sucrose> Water] and [0.10 M Sucrose> Water] were estimated across all three scans of each concentration and entered into an SPM8 group random effects factorial model, Family History (FHP, FHN) × Sex (Men, Women) × Sucrose Concentration (high, low), permitting secondary analyses of any effects from sex.
61-1	10946-10957	Statistical	_
61-2	10958-10966	analysis	_
61-3	10967-10970	The	_
61-4	10971-10980	contrasts	_
61-5	10981-10983	of	_
61-6	10984-10985	[	_
61-7	10986-10990	0.83	_
61-8	10991-10992	M	_
61-9	10993-11000	Sucrose	_
61-10	11001-11002	>	_
61-11	11003-11008	Water	_
61-12	11009-11010	]	_
61-13	11011-11014	and	_
61-14	11015-11016	[	_
61-15	11017-11021	0.10	_
61-16	11022-11023	M	_
61-17	11024-11031	Sucrose	_
61-18	11032-11033	>	_
61-19	11034-11039	Water	_
61-20	11040-11041	]	_
61-21	11042-11046	were	_
61-22	11047-11056	estimated	_
61-23	11057-11063	across	_
61-24	11064-11067	all	_
61-25	11068-11073	three	_
61-26	11074-11079	scans	_
61-27	11080-11082	of	_
61-28	11083-11087	each	_
61-29	11088-11101	concentration	_
61-30	11102-11105	and	_
61-31	11106-11113	entered	_
61-32	11114-11118	into	_
61-33	11119-11121	an	_
61-34	11122-11126	SPM8	_
61-35	11127-11132	group	_
61-36	11133-11139	random	_
61-37	11140-11147	effects	_
61-38	11148-11157	factorial	_
61-39	11158-11163	model	_
61-40	11164-11165	,	_
61-41	11166-11172	Family	_
61-42	11173-11180	History	_
61-43	11181-11182	(	_
61-44	11183-11186	FHP	_
61-45	11187-11188	,	_
61-46	11189-11192	FHN	_
61-47	11193-11194	)	_
61-48	11195-11196	×	_
61-49	11197-11200	Sex	_
61-50	11201-11202	(	_
61-51	11203-11206	Men	_
61-52	11207-11208	,	_
61-53	11209-11214	Women	_
61-54	11215-11216	)	_
61-55	11217-11218	×	_
61-56	11219-11226	Sucrose	_
61-57	11227-11240	Concentration	_
61-58	11241-11242	(	_
61-59	11243-11247	high	_
61-60	11248-11249	,	_
61-61	11250-11253	low	_
61-62	11254-11255	)	_
61-63	11256-11257	,	_
61-64	11258-11268	permitting	_
61-65	11269-11278	secondary	_
61-66	11279-11287	analyses	_
61-67	11288-11290	of	_
61-68	11291-11294	any	_
61-69	11295-11302	effects	_
61-70	11303-11307	from	_
61-71	11308-11311	sex	_
61-72	11312-11313	.	_

Text=We also examined an SPM factorial model that included drinks/week as normalized by total body water to account for differences in body size in sex, and thus alcohol exposure.
62-1	11314-11316	We	_
62-2	11317-11321	also	_
62-3	11322-11330	examined	_
62-4	11331-11333	an	_
62-5	11334-11337	SPM	_
62-6	11338-11347	factorial	_
62-7	11348-11353	model	_
62-8	11354-11358	that	_
62-9	11359-11367	included	_
62-10	11368-11379	drinks/week	_
62-11	11380-11382	as	_
62-12	11383-11393	normalized	_
62-13	11394-11396	by	_
62-14	11397-11402	total	_
62-15	11403-11407	body	_
62-16	11408-11413	water	_
62-17	11414-11416	to	_
62-18	11417-11424	account	_
62-19	11425-11428	for	_
62-20	11429-11440	differences	_
62-21	11441-11443	in	_
62-22	11444-11448	body	_
62-23	11449-11453	size	_
62-24	11454-11456	in	_
62-25	11457-11460	sex	_
62-26	11461-11462	,	_
62-27	11463-11466	and	_
62-28	11467-11471	thus	_
62-29	11472-11479	alcohol	_
62-30	11480-11488	exposure	_
62-31	11489-11490	.	_

Text=In addition, the covariates of both drinks/week and drinks/drinking day (normalized by total body water) were tested for any associations with BOLD responses to determine if the preliminary effects we previously identified could be replicated.
63-1	11491-11493	In	_
63-2	11494-11502	addition	_
63-3	11503-11504	,	_
63-4	11505-11508	the	_
63-5	11509-11519	covariates	_
63-6	11520-11522	of	_
63-7	11523-11527	both	_
63-8	11528-11539	drinks/week	_
63-9	11540-11543	and	_
63-10	11544-11559	drinks/drinking	_
63-11	11560-11563	day	_
63-12	11564-11565	(	_
63-13	11566-11576	normalized	_
63-14	11577-11579	by	_
63-15	11580-11585	total	_
63-16	11586-11590	body	_
63-17	11591-11596	water	_
63-18	11597-11598	)	_
63-19	11599-11603	were	_
63-20	11604-11610	tested	_
63-21	11611-11614	for	_
63-22	11615-11618	any	_
63-23	11619-11631	associations	_
63-24	11632-11636	with	_
63-25	11637-11641	BOLD	_
63-26	11642-11651	responses	_
63-27	11652-11654	to	_
63-28	11655-11664	determine	_
63-29	11665-11667	if	_
63-30	11668-11671	the	_
63-31	11672-11683	preliminary	_
63-32	11684-11691	effects	_
63-33	11692-11694	we	_
63-34	11695-11705	previously	_
63-35	11706-11716	identified	_
63-36	11717-11722	could	_
63-37	11723-11725	be	_
63-38	11726-11736	replicated	_
63-39	11737-11738	.	_

Text=For ease of interpretation, however, we also present drinking data that are unadjusted by total body water (see Table 1).
64-1	11739-11742	For	_
64-2	11743-11747	ease	_
64-3	11748-11750	of	_
64-4	11751-11765	interpretation	_
64-5	11766-11767	,	_
64-6	11768-11775	however	_
64-7	11776-11777	,	_
64-8	11778-11780	we	_
64-9	11781-11785	also	_
64-10	11786-11793	present	_
64-11	11794-11802	drinking	_
64-12	11803-11807	data	_
64-13	11808-11812	that	_
64-14	11813-11816	are	_
64-15	11817-11827	unadjusted	_
64-16	11828-11830	by	_
64-17	11831-11836	total	_
64-18	11837-11841	body	_
64-19	11842-11847	water	_
64-20	11848-11849	(	_
64-21	11850-11853	see	_
64-22	11854-11859	Table	_
64-23	11860-11861	1	_
64-24	11862-11863	)	_
64-25	11864-11865	.	_

Text=To identify only those gustatory areas present in the current data set, we made statistical inferences for the main effect of sucrose (collapsed across Family History, Sex, and Concentration) at the voxel-wise height threshold pFWE <0.05, correcting for family-wise error (FWE) from multiple comparisons across the whole brain volume.
65-1	11866-11868	To	_
65-2	11869-11877	identify	_
65-3	11878-11882	only	_
65-4	11883-11888	those	_
65-5	11889-11898	gustatory	_
65-6	11899-11904	areas	_
65-7	11905-11912	present	_
65-8	11913-11915	in	_
65-9	11916-11919	the	_
65-10	11920-11927	current	_
65-11	11928-11932	data	_
65-12	11933-11936	set	_
65-13	11937-11938	,	_
65-14	11939-11941	we	_
65-15	11942-11946	made	_
65-16	11947-11958	statistical	_
65-17	11959-11969	inferences	_
65-18	11970-11973	for	_
65-19	11974-11977	the	_
65-20	11978-11982	main	_
65-21	11983-11989	effect	_
65-22	11990-11992	of	_
65-23	11993-12000	sucrose	_
65-24	12001-12002	(	_
65-25	12003-12012	collapsed	_
65-26	12013-12019	across	_
65-27	12020-12026	Family	_
65-28	12027-12034	History	_
65-29	12035-12036	,	_
65-30	12037-12040	Sex	_
65-31	12041-12042	,	_
65-32	12043-12046	and	_
65-33	12047-12060	Concentration	_
65-34	12061-12062	)	_
65-35	12063-12065	at	_
65-36	12066-12069	the	_
65-37	12070-12080	voxel-wise	_
65-38	12081-12087	height	_
65-39	12088-12097	threshold	_
65-40	12098-12102	pFWE	_
65-41	12103-12104	<	_
65-42	12105-12109	0.05	_
65-43	12110-12111	,	_
65-44	12112-12122	correcting	_
65-45	12123-12126	for	_
65-46	12127-12138	family-wise	_
65-47	12139-12144	error	_
65-48	12145-12146	(	_
65-49	12147-12150	FWE	_
65-50	12151-12152	)	_
65-51	12153-12157	from	_
65-52	12158-12166	multiple	_
65-53	12167-12178	comparisons	_
65-54	12179-12185	across	_
65-55	12186-12189	the	_
65-56	12190-12195	whole	_
65-57	12196-12201	brain	_
65-58	12202-12208	volume	_
65-59	12209-12210	.	_

Text=This was the only contrast assessed across the whole brain volume, and solely to demonstrate that the paradigm activated the gustatory system overall (positive control).
66-1	12211-12215	This	_
66-2	12216-12219	was	_
66-3	12220-12223	the	_
66-4	12224-12228	only	_
66-5	12229-12237	contrast	_
66-6	12238-12246	assessed	_
66-7	12247-12253	across	_
66-8	12254-12257	the	_
66-9	12258-12263	whole	_
66-10	12264-12269	brain	_
66-11	12270-12276	volume	_
66-12	12277-12278	,	_
66-13	12279-12282	and	_
66-14	12283-12289	solely	_
66-15	12290-12292	to	_
66-16	12293-12304	demonstrate	_
66-17	12305-12309	that	_
66-18	12310-12313	the	_
66-19	12314-12322	paradigm	_
66-20	12323-12332	activated	_
66-21	12333-12336	the	_
66-22	12337-12346	gustatory	_
66-23	12347-12353	system	_
66-24	12354-12361	overall	_
66-25	12362-12363	(	_
66-26	12364-12372	positive	_
66-27	12373-12380	control	_
66-28	12381-12382	)	_
66-29	12383-12384	.	_

Text=To test for effects related to family history, we created a mask from regions previously defined by work published elsewhere (i.e., the current data were not used to generate the mask).
67-1	12385-12387	To	_
67-2	12388-12392	test	_
67-3	12393-12396	for	_
67-4	12397-12404	effects	_
67-5	12405-12412	related	_
67-6	12413-12415	to	_
67-7	12416-12422	family	_
67-8	12423-12430	history	_
67-9	12431-12432	,	_
67-10	12433-12435	we	_
67-11	12436-12443	created	_
67-12	12444-12445	a	_
67-13	12446-12450	mask	_
67-14	12451-12455	from	_
67-15	12456-12463	regions	_
67-16	12464-12474	previously	_
67-17	12475-12482	defined	_
67-18	12483-12485	by	_
67-19	12486-12490	work	_
67-20	12491-12500	published	_
67-21	12501-12510	elsewhere	_
67-22	12511-12512	(	_
67-23	12513-12517	i.e.	_
67-24	12518-12519	,	_
67-25	12520-12523	the	_
67-26	12524-12531	current	_
67-27	12532-12536	data	_
67-28	12537-12541	were	_
67-29	12542-12545	not	_
67-30	12546-12550	used	_
67-31	12551-12553	to	_
67-32	12554-12562	generate	_
67-33	12563-12566	the	_
67-34	12567-12571	mask	_
67-35	12572-12573	)	_
67-36	12574-12575	.	_

Text=This 9792 mm3 (1224 voxels) conjoint binary mask (Fig.
68-1	12576-12580	This	_
68-2	12581-12585	9792	_
68-3	12586-12589	mm3	_
68-4	12590-12591	(	_
68-5	12592-12596	1224	_
68-6	12597-12603	voxels	_
68-7	12604-12605	)	_
68-8	12606-12614	conjoint	_
68-9	12615-12621	binary	_
68-10	12622-12626	mask	_
68-11	12627-12628	(	_
68-12	12629-12632	Fig	_
68-13	12633-12634	.	_

Text=S1) used for family wise error correction comprised of a priori hypothesized bilateral ROIs covering: (a) gustatory regions of “ area-G ” (insula/parietal junction) and peri-Rolandic parietal areas identified by, (b) amygdala as identified by the MarsBar utility (AAL Atlas), (c) posterior orbitofrontal areas identified by the meta-analysis as responding to primary reinforcers, and (d) previously described ventral striatal regions.
69-1	12635-12637	S1	_
69-2	12638-12639	)	_
69-3	12640-12644	used	_
69-4	12645-12648	for	_
69-5	12649-12655	family	_
69-6	12656-12660	wise	_
69-7	12661-12666	error	_
69-8	12667-12677	correction	_
69-9	12678-12687	comprised	_
69-10	12688-12690	of	_
69-11	12691-12692	a	_
69-12	12693-12699	priori	_
69-13	12700-12712	hypothesized	_
69-14	12713-12722	bilateral	_
69-15	12723-12727	ROIs	_
69-16	12728-12736	covering	_
69-17	12737-12738	:	_
69-18	12739-12740	(	_
69-19	12741-12742	a	_
69-20	12743-12744	)	_
69-21	12745-12754	gustatory	_
69-22	12755-12762	regions	_
69-23	12763-12765	of	_
69-24	12766-12767	“	_
69-25	12768-12774	area-G	_
69-26	12775-12776	”	_
69-27	12777-12778	(	_
69-28	12779-12794	insula/parietal	_
69-29	12795-12803	junction	_
69-30	12804-12805	)	_
69-31	12806-12809	and	_
69-32	12810-12823	peri-Rolandic	_
69-33	12824-12832	parietal	_
69-34	12833-12838	areas	_
69-35	12839-12849	identified	_
69-36	12850-12852	by	_
69-37	12853-12854	,	_
69-38	12855-12856	(	_
69-39	12857-12858	b	_
69-40	12859-12860	)	_
69-41	12861-12869	amygdala	_
69-42	12870-12872	as	_
69-43	12873-12883	identified	_
69-44	12884-12886	by	_
69-45	12887-12890	the	_
69-46	12891-12898	MarsBar	_
69-47	12899-12906	utility	_
69-48	12907-12908	(	_
69-49	12909-12912	AAL	_
69-50	12913-12918	Atlas	_
69-51	12919-12920	)	_
69-52	12921-12922	,	_
69-53	12923-12924	(	_
69-54	12925-12926	c	_
69-55	12927-12928	)	_
69-56	12929-12938	posterior	_
69-57	12939-12952	orbitofrontal	_
69-58	12953-12958	areas	_
69-59	12959-12969	identified	_
69-60	12970-12972	by	_
69-61	12973-12976	the	_
69-62	12977-12990	meta-analysis	_
69-63	12991-12993	as	_
69-64	12994-13004	responding	_
69-65	13005-13007	to	_
69-66	13008-13015	primary	_
69-67	13016-13027	reinforcers	_
69-68	13028-13029	,	_
69-69	13030-13033	and	_
69-70	13034-13035	(	_
69-71	13036-13037	d	_
69-72	13038-13039	)	_
69-73	13040-13050	previously	_
69-74	13051-13060	described	_
69-75	13061-13068	ventral	_
69-76	13069-13077	striatal	_
69-77	13078-13085	regions	_
69-78	13086-13087	.	_

Text=All subsequent analyses of BOLD response (i.e., all those beyond the main effect of sucrose stimulation, described above) were conducted using this independent conjoint mask for small volume correction with a height threshold of pFWE <0.05.
70-1	13088-13091	All	_
70-2	13092-13102	subsequent	_
70-3	13103-13111	analyses	_
70-4	13112-13114	of	_
70-5	13115-13119	BOLD	_
70-6	13120-13128	response	_
70-7	13129-13130	(	_
70-8	13131-13135	i.e.	_
70-9	13136-13137	,	_
70-10	13138-13141	all	_
70-11	13142-13147	those	_
70-12	13148-13154	beyond	_
70-13	13155-13158	the	_
70-14	13159-13163	main	_
70-15	13164-13170	effect	_
70-16	13171-13173	of	_
70-17	13174-13181	sucrose	_
70-18	13182-13193	stimulation	_
70-19	13194-13195	,	_
70-20	13196-13205	described	_
70-21	13206-13211	above	_
70-22	13212-13213	)	_
70-23	13214-13218	were	_
70-24	13219-13228	conducted	_
70-25	13229-13234	using	_
70-26	13235-13239	this	_
70-27	13240-13251	independent	_
70-28	13252-13260	conjoint	_
70-29	13261-13265	mask	_
70-30	13266-13269	for	_
70-31	13270-13275	small	_
70-32	13276-13282	volume	_
70-33	13283-13293	correction	_
70-34	13294-13298	with	_
70-35	13299-13300	a	_
70-36	13301-13307	height	_
70-37	13308-13317	threshold	_
70-38	13318-13320	of	_
70-39	13321-13325	pFWE	_
70-40	13326-13327	<	_
70-41	13328-13332	0.05	_
70-42	13333-13334	.	_

Text=Finally, we used voxel-wise linear regression to test for associations between rated sucrose liking and brain activation.
71-1	13335-13342	Finally	_
71-2	13343-13344	,	_
71-3	13345-13347	we	_
71-4	13348-13352	used	_
71-5	13353-13363	voxel-wise	_
71-6	13364-13370	linear	_
71-7	13371-13381	regression	_
71-8	13382-13384	to	_
71-9	13385-13389	test	_
71-10	13390-13393	for	_
71-11	13394-13406	associations	_
71-12	13407-13414	between	_
71-13	13415-13420	rated	_
71-14	13421-13428	sucrose	_
71-15	13429-13435	liking	_
71-16	13436-13439	and	_
71-17	13440-13445	brain	_
71-18	13446-13456	activation	_
71-19	13457-13458	.	_

Text=Subject group demographic data were analyzed using Family History (2) × Sex (2) general linear models.
72-1	13459-13466	Subject	_
72-2	13467-13472	group	_
72-3	13473-13484	demographic	_
72-4	13485-13489	data	_
72-5	13490-13494	were	_
72-6	13495-13503	analyzed	_
72-7	13504-13509	using	_
72-8	13510-13516	Family	_
72-9	13517-13524	History	_
72-10	13525-13526	(	_
72-11	13527-13528	2	_
72-12	13529-13530	)	_
72-13	13531-13532	×	_
72-14	13533-13536	Sex	_
72-15	13537-13538	(	_
72-16	13539-13540	2	_
72-17	13541-13542	)	_
72-18	13543-13550	general	_
72-19	13551-13557	linear	_
72-20	13558-13564	models	_
72-21	13565-13566	.	_

Text=Taste test data outside the scanner were analyzed by a Family History (2) × Sex (2) × Concentration (5) × Block (3) mixed linear model, with concentration and block being repeated measures.
73-1	13567-13572	Taste	_
73-2	13573-13577	test	_
73-3	13578-13582	data	_
73-4	13583-13590	outside	_
73-5	13591-13594	the	_
73-6	13595-13602	scanner	_
73-7	13603-13607	were	_
73-8	13608-13616	analyzed	_
73-9	13617-13619	by	_
73-10	13620-13621	a	_
73-11	13622-13628	Family	_
73-12	13629-13636	History	_
73-13	13637-13638	(	_
73-14	13639-13640	2	_
73-15	13641-13642	)	_
73-16	13643-13644	×	_
73-17	13645-13648	Sex	_
73-18	13649-13650	(	_
73-19	13651-13652	2	_
73-20	13653-13654	)	_
73-21	13655-13656	×	_
73-22	13657-13670	Concentration	_
73-23	13671-13672	(	_
73-24	13673-13674	5	_
73-25	13675-13676	)	_
73-26	13677-13678	×	_
73-27	13679-13684	Block	_
73-28	13685-13686	(	_
73-29	13687-13688	3	_
73-30	13689-13690	)	_
73-31	13691-13696	mixed	_
73-32	13697-13703	linear	_
73-33	13704-13709	model	_
73-34	13710-13711	,	_
73-35	13712-13716	with	_
73-36	13717-13730	concentration	_
73-37	13731-13734	and	_
73-38	13735-13740	block	_
73-39	13741-13746	being	_
73-40	13747-13755	repeated	_
73-41	13756-13764	measures	_
73-42	13765-13766	.	_

Text=Additional models including drinks/week and drinks/drinking day (each corrected by total body water) covariates were also used to test for the covariate effects.
74-1	13767-13777	Additional	_
74-2	13778-13784	models	_
74-3	13785-13794	including	_
74-4	13795-13806	drinks/week	_
74-5	13807-13810	and	_
74-6	13811-13826	drinks/drinking	_
74-7	13827-13830	day	_
74-8	13831-13832	(	_
74-9	13833-13837	each	_
74-10	13838-13847	corrected	_
74-11	13848-13850	by	_
74-12	13851-13856	total	_
74-13	13857-13861	body	_
74-14	13862-13867	water	_
74-15	13868-13869	)	_
74-16	13870-13880	covariates	_
74-17	13881-13885	were	_
74-18	13886-13890	also	_
74-19	13891-13895	used	_
74-20	13896-13898	to	_
74-21	13899-13903	test	_
74-22	13904-13907	for	_
74-23	13908-13911	the	_
74-24	13912-13921	covariate	_
74-25	13922-13929	effects	_
74-26	13930-13931	.	_

Text=Intra-MRI ratings of hunger, thirst, craving for sweet and salty tastes, and desire to change sweetness were analyzed using a Family History (FHP, FHN) × Sex (Men, Women) × Time (Baseline, First Scan, Last Scan) × Concentration (pre-exposure, 0.10 M, 0.83 M) mixed linear model, with Time and Concentration being repeated measures.
75-1	13932-13941	Intra-MRI	_
75-2	13942-13949	ratings	_
75-3	13950-13952	of	_
75-4	13953-13959	hunger	_
75-5	13960-13961	,	_
75-6	13962-13968	thirst	_
75-7	13969-13970	,	_
75-8	13971-13978	craving	_
75-9	13979-13982	for	_
75-10	13983-13988	sweet	_
75-11	13989-13992	and	_
75-12	13993-13998	salty	_
75-13	13999-14005	tastes	_
75-14	14006-14007	,	_
75-15	14008-14011	and	_
75-16	14012-14018	desire	_
75-17	14019-14021	to	_
75-18	14022-14028	change	_
75-19	14029-14038	sweetness	_
75-20	14039-14043	were	_
75-21	14044-14052	analyzed	_
75-22	14053-14058	using	_
75-23	14059-14060	a	_
75-24	14061-14067	Family	_
75-25	14068-14075	History	_
75-26	14076-14077	(	_
75-27	14078-14081	FHP	_
75-28	14082-14083	,	_
75-29	14084-14087	FHN	_
75-30	14088-14089	)	_
75-31	14090-14091	×	_
75-32	14092-14095	Sex	_
75-33	14096-14097	(	_
75-34	14098-14101	Men	_
75-35	14102-14103	,	_
75-36	14104-14109	Women	_
75-37	14110-14111	)	_
75-38	14112-14113	×	_
75-39	14114-14118	Time	_
75-40	14119-14120	(	_
75-41	14121-14129	Baseline	_
75-42	14130-14131	,	_
75-43	14132-14137	First	_
75-44	14138-14142	Scan	_
75-45	14143-14144	,	_
75-46	14145-14149	Last	_
75-47	14150-14154	Scan	_
75-48	14155-14156	)	_
75-49	14157-14158	×	_
75-50	14159-14172	Concentration	_
75-51	14173-14174	(	_
75-52	14175-14187	pre-exposure	_
75-53	14188-14189	,	_
75-54	14190-14194	0.10	_
75-55	14195-14196	M	_
75-56	14197-14198	,	_
75-57	14199-14203	0.83	_
75-58	14204-14205	M	_
75-59	14206-14207	)	_
75-60	14208-14213	mixed	_
75-61	14214-14220	linear	_
75-62	14221-14226	model	_
75-63	14227-14228	,	_
75-64	14229-14233	with	_
75-65	14234-14238	Time	_
75-66	14239-14242	and	_
75-67	14243-14256	Concentration	_
75-68	14257-14262	being	_
75-69	14263-14271	repeated	_
75-70	14272-14280	measures	_
75-71	14281-14282	.	_

Text=Perceived sweetness and sweet liking were analyzed with Family History (FHP, FHN) × Sex (Men, Women) × Time (First Scan, Last Scan) × Concentration (0.10 M, 0.83 M) mixed linear models.
76-1	14283-14292	Perceived	_
76-2	14293-14302	sweetness	_
76-3	14303-14306	and	_
76-4	14307-14312	sweet	_
76-5	14313-14319	liking	_
76-6	14320-14324	were	_
76-7	14325-14333	analyzed	_
76-8	14334-14338	with	_
76-9	14339-14345	Family	_
76-10	14346-14353	History	_
76-11	14354-14355	(	_
76-12	14356-14359	FHP	_
76-13	14360-14361	,	_
76-14	14362-14365	FHN	_
76-15	14366-14367	)	_
76-16	14368-14369	×	_
76-17	14370-14373	Sex	_
76-18	14374-14375	(	_
76-19	14376-14379	Men	_
76-20	14380-14381	,	_
76-21	14382-14387	Women	_
76-22	14388-14389	)	_
76-23	14390-14391	×	_
76-24	14392-14396	Time	_
76-25	14397-14398	(	_
76-26	14399-14404	First	_
76-27	14405-14409	Scan	_
76-28	14410-14411	,	_
76-29	14412-14416	Last	_
76-30	14417-14421	Scan	_
76-31	14422-14423	)	_
76-32	14424-14425	×	_
76-33	14426-14439	Concentration	_
76-34	14440-14441	(	_
76-35	14442-14446	0.10	_
76-36	14447-14448	M	_
76-37	14449-14450	,	_
76-38	14451-14455	0.83	_
76-39	14456-14457	M	_
76-40	14458-14459	)	_
76-41	14460-14465	mixed	_
76-42	14466-14472	linear	_
76-43	14473-14479	models	_
76-44	14480-14481	.	_

Text=To test for associations between drinking and rated liking of the sweet solutions inside the scanner, the covariates of drinks/week and drinks/drinking day (both adjusted for total body water) were also used.
77-1	14482-14484	To	_
77-2	14485-14489	test	_
77-3	14490-14493	for	_
77-4	14494-14506	associations	_
77-5	14507-14514	between	_
77-6	14515-14523	drinking	_
77-7	14524-14527	and	_
77-8	14528-14533	rated	_
77-9	14534-14540	liking	_
77-10	14541-14543	of	_
77-11	14544-14547	the	_
77-12	14548-14553	sweet	_
77-13	14554-14563	solutions	_
77-14	14564-14570	inside	_
77-15	14571-14574	the	_
77-16	14575-14582	scanner	_
77-17	14583-14584	,	_
77-18	14585-14588	the	_
77-19	14589-14599	covariates	_
77-20	14600-14602	of	_
77-21	14603-14614	drinks/week	_
77-22	14615-14618	and	_
77-23	14619-14634	drinks/drinking	_
77-24	14635-14638	day	_
77-25	14639-14640	(	_
77-26	14641-14645	both	_
77-27	14646-14654	adjusted	_
77-28	14655-14658	for	_
77-29	14659-14664	total	_
77-30	14665-14669	body	_
77-31	14670-14675	water	_
77-32	14676-14677	)	_
77-33	14678-14682	were	_
77-34	14683-14687	also	_
77-35	14688-14692	used	_
77-36	14693-14694	.	_

Text=When examining these covariates, and for ease of interpretation, the models were simplified by removing the Concentration factor, with two different models for each concentration (0.10 M, 0.83 M).
78-1	14695-14699	When	_
78-2	14700-14709	examining	_
78-3	14710-14715	these	_
78-4	14716-14726	covariates	_
78-5	14727-14728	,	_
78-6	14729-14732	and	_
78-7	14733-14736	for	_
78-8	14737-14741	ease	_
78-9	14742-14744	of	_
78-10	14745-14759	interpretation	_
78-11	14760-14761	,	_
78-12	14762-14765	the	_
78-13	14766-14772	models	_
78-14	14773-14777	were	_
78-15	14778-14788	simplified	_
78-16	14789-14791	by	_
78-17	14792-14800	removing	_
78-18	14801-14804	the	_
78-19	14805-14818	Concentration	_
78-20	14819-14825	factor	_
78-21	14826-14827	,	_
78-22	14828-14832	with	_
78-23	14833-14836	two	_
78-24	14837-14846	different	_
78-25	14847-14853	models	_
78-26	14854-14857	for	_
78-27	14858-14862	each	_
78-28	14863-14876	concentration	_
78-29	14877-14878	(	_
78-30	14879-14883	0.10	_
78-31	14884-14885	M	_
78-32	14886-14887	,	_
78-33	14888-14892	0.83	_
78-34	14893-14894	M	_
78-35	14895-14896	)	_
78-36	14897-14898	.	_

